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Abstract 
Introduction: Multimorbidity, the presence of two or more chronic diseases in an individual, is a 
pressing medical condition. Novel prevention methods are required to reduce the incidence of 
multimorbidity. Prognostic predictive models estimate a patient’s risk of developing chronic 
disease. This thesis developed a single predictive model for three diseases associated with 
multimorbidity: diabetes, hypertension, and osteoarthritis. 
Methods: Univariate logistic regression models were constructed, followed by an analysis of the 
dependence that existed using copulas. All analyses were based on data from the Canadian 
Primary Care Sentinel Surveillance Network. 
Results: All univariate models were highly predictive, as demonstrated by their discrimination 
and calibration. Copula models revealed the dependence between each disease pair.  
Discussion: By estimating the risk of multiple chronic diseases, prognostic predictive models 
may enable the prevention of chronic disease through identification of high-risk individuals or 
delivery of individualized risk assessments to inform patient and health care provider decision-
making. 
Keywords 
Multimorbidity, Chronic disease, Diabetes, Hypertension, Osteoarthritis, Risk prediction, 
Prognostic predictive model, Electronic medical records, CPCSSN 
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Chapter 1  
1 Introduction 
Prognostic predictive models (PPM) estimate a patient’s risk for future disease development 
based on the patient’s current predictors of disease (1,2). Potential predictors, including patient 
demographics, family history, lifestyle factors, medical conditions, or genetic factors (3), are 
used to produce risk estimates of disease. These estimates can be used by primary care 
practitioners (PCP) in their primary prevention activities with patients (4,5). Many chronic 
diseases have been accurately predicted through risk estimation using prognostic predictive 
models (6–8), such as cardiovascular disease (7,9). These tools have been shown to improve 
patients’ risk perception and knowledge (10), as well as to modify PCP care, including 
prescribing behaviours (11). The objective of a PPM is to inform patient and PCP decision-
making by providing risk estimations and identifying high-risk individuals to target with risk-
reducing interventions, thereby reducing the future incidence of disease. 
The occurrence of two or more chronic diseases within a single patient, or multimorbidity, is a 
growing concern in the health care community. Prevalence estimates vary due to inconsistent 
definitions of multimorbidity; levels in Canadian older adults range from 55 to 98% (12). 
Methods of preventing the development of multimorbidity are severely lacking (13); novel 
methods of prevention must be developed to reduce future incidence. One potential method that 
may aid in preventing future cases of multimorbidity is the use of prognostic predictive models 
aimed at informing patients and their care providers about multimorbidity risk.  
A prognostic predictive model capable of estimating the risk of multiple diseases simultaneously 
would deliver a comprehensive risk assessment that could be used to identify patients at highest 
risk of disease in general. This model would incorporate aspects beyond risk factors for 
individual diseases when estimating risk; for example, prior morbidities would be included as 
predictors. Risk estimates produced by this model would include more than an overall risk of 
disease; it would present a comprehensive description of patient risk for multiple outcomes, 
including high-risk individual diseases, common disease pairings, and/or common clusters of 
chronic disease. In the past, the development of models capable of estimating risk of multiple 
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diseases has been restricted by the lack of datasets large enough and rich enough to support the 
production of such estimates. Recently established large-scale electronic medical record (EMR) 
databases (14–17) represent a potential source of data of the size necessary to support efforts in 
multimorbidity risk modelling.  
Primary prevention is one of the fundamental goals of primary care (18), making primary care an 
ideal setting to deploy such methods to reduce multimorbidity risk. Modelling risk of multiple 
diseases could impact clinical practice twofold. First, it would identify patients at highest risk, 
allowing the PCP to target these patients with risk-reducing interventions (19). Second, 
practitioners and patients are often tasked with determining which risk factors are of the greatest 
importance, as these should be targeted first. Risk modelling of multiple diseases would identify 
risk factors that significantly contribute to the risk of multiple diseases to maximize the impact of 
risk factor modification and reduce intervention-burden on patients. It is hoped that these 
targeted interventions will help prevent future incidence of multimorbidity. 
Traditionally, risk is modelled for individual diseases under the assumption that disease develops 
independent of other diseases; however, we know from the study of multimorbidity that this 
assumption is often false. Occurrence of diseases in the same individual is not an independent 
event; disease processes influence the development or progression of other diseases leading to 
chronic diseases often occurring together (20–22). For this reason, the estimation of disease risk 
under the assumption that disease occurrences are independent events does not accurately reflect 
a patient’s true risk of disease. Therefore, an understanding of the dependence that exists 
between each disease is required prior to the construction of a prognostic predictive model for 
multiple chronic diseases. Given this, models can be built to describe the dependence between 
multiple diseases and estimate their risk of occurring in the same individual. The two main goals 
of this work are 1) to build a prognostic predictive model that both accounts for existing chronic 
disease and predicts the occurrence of multiple diseases simultaneously and 2) to examine the 
dependence that exists between three chronic diseases – diabetes, hypertension, and osteoarthritis 
– after adjusting for known risk factors. To achieve this, two objectives were identified: 1) to 
construct a univariate multivariable logistic regression model for each chronic disease, which 
allowed for 2) the construction of a copula that captures their joint dependence after adjusting for 
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risk factors. The resulting model achieves both goals, since it can be used to make risk 
predictions and it can be used to assess dependence in disease development. 
This thesis first explores chronic disease, namely multimorbidity, and the possibility of 
predicting multiple diseases using prognostic predictive models. Electronic medical records are 
discussed as a potential data source. Subsequently, the methods of developing such a model are 
presented, followed by the resulting model. Finally, the model that was developed for this thesis 
is compared to existing research into prognostic predictive models and multiple diseases. In 
addition, the limitations and implications of the model produced for this thesis are discussed. 
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Chapter 2  
2 Literature Review 
The following literature review first describes chronic disease, particularly multimorbidity, and 
its impacts. It continues by presenting prognostic predictive models as a potential method of 
supporting the primary prevention of chronic disease and multimorbidity. It then finishes by 
describing two requirements of multiple disease risk estimation: advanced statistical 
methodologies and electronic medical record data. 
2.1 Chronic Disease 
As the leading cause of death worldwide, chronic disease represents one of the world’s largest 
challenges (23). Disease is categorized into two distinct types: chronic and acute. Acute diseases 
are characterized by their short duration. Patients typically recover from their disease within a 
brief period of time (24); the length of this period is dependent upon the disease context. Acute 
diseases are most often communicable, or transmitted from person to person, and thus commonly 
referred to as “communicable diseases”. On the other hand, chronic diseases are long-lasting in 
duration. Patients recover from their disease only after an extended period of time, if ever; many 
chronic diseases are lifelong diseases. Chronic diseases are most commonly non-communicable, 
or not transmitted from person to person. There are some exceptions to this, most notably 
HIV/AIDS (25). In the past, acute infectious diseases were the main cause of morbidity and 
mortality, globally. Typhoid, cholera, smallpox, tuberculosis, and diphtheria, among other 
infectious and parasitic diseases were common until the early twentieth century (25). Due to 
recent advancements in health care and the ability to treat (and often cure) infectious diseases, 
such as the advent of antibiotics and vaccines and improvements in housing, sanitation, water 
supply, and nutrition, rates of infectious diseases have severely fallen. However, due to the 
increased lifespan resulting from the factors mentioned, there has been a concurrent rise in the 
occurrence of chronic diseases. Chronic diseases such as cardiovascular disease, cancer, and 
COPD are among the leading causes of death for developed nations (25). One of the main 
focuses of today’s health care efforts is the treatment and prevention of chronic diseases. 
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2.1.1 Definition 
There is no single, agreed upon definition of chronic disease (26). Most definitions depend on 
either disease duration or disease transmission; however, these definitions will produce 
inconsistent classifications of disease. As described above, HIV is a communicable disease for 
which no cure exists that results in lifelong health effects.  Many organizations have constructed 
definitions of chronic disease and lists of diseases they consider chronic diseases. These 
definitions are often non-specific; for example, the U.S. National Center for Health Statistics 
defines chronic disease as “a disease lasting 3 months or longer” (27). Additionally, these 
definitions often disagree. The Public Health Agency of Canada considers five main groups of 
chronic diseases: cardiovascular diseases, cancers, chronic respiratory diseases, diabetes, and 
mood and anxiety disorders (28). By the U.S. National Center for Health Statistics definition, 
diseases such as epilepsy or chronic kidney disease would be considered chronic diseases, 
whereas by the Public Health Agency of Canada definition they would not.  
Given this lack of a standard definition of chronic disease, it is not possible to use it as an 
outcome for prediction without significant additional effort. However, this thesis was not subject 
to this issue as it simply selected three diseases for prediction that are managed in primary care 
and possess lifelong clinical implications. The methodology in the thesis is general and can be 
applied to any outcome of interest. 
2.1.2 Prevalence 
In Canada, greater than one fifth of Canadians age twenty or older live with at least one major 
chronic disease (CVD, cancer, chronic respiratory disease, and diabetes) (29). In Canadians aged 
65 or older, this proportion of individuals living with at least one major chronic disease grows to 
over 40% (29). 
2.1.3 Risk Factors 
A risk factor is some characteristic that is causally associated with a given disease; these can be 
environmental, genetic, behavioural, somatic, or social. Risk factors are distinct from risk 
markers, which are associated with risk of disease non-causally or of unproven causation (30). 
Risk factors must be proven to be causally associated with risk of disease through the use of 
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epidemiologic methods.  For example, smoking has been shown to impart an increased risk for 
lung cancer (31), making it a risk factor. Identification of risk factors is important for two 
reasons; it allows for 1) risk assessments in which an individual’s risk factors are assessed to 
enable risk estimation and 2) subsequent intervention upon modifiable risk factors. Most diseases 
are multifactorial (i.e., their development is influenced by multiple risk factors). Indeed, it is 
common for individuals to have more than one risk factor. When an individual possesses 
multiple risk factors, these risk factors can have an additive or multiplicative impact on risk; this 
effect is known as interaction. When risk factors interact in an additive manner, the individual’s 
total risk is greater or less than the sum of the component risks (32). When risk factors interact in 
a multiplicative manner, the individual’s total risk is greater or less than the product of the 
component risks (32). Risk factors are often targeted with interventions aimed at reducing a 
person’s risk of developing chronic disease. 
Risk factors can be modifiable or non-modifiable. Modifiable risk factors can be changed 
through some intervention. Interventions often include behavioural or lifestyle changes, medical 
procedures, or pharmaceutical treatments. For example, smoking is a risk factor for 
cardiovascular disease, which can be modified by quitting smoking; studies have demonstrated 
that quitting smoking reduces the risk of developing cardiovascular disease (33,34). Non-
modifiable risk factors cannot be changed. For example, family history is non-modifiable risk 
factor for cardiovascular disease. Intervention upon risk factors is the focus of primary 
prevention efforts, which aim to lower an individual’s risk of developing disease. 
Many chronic diseases share common risk factors. For example, obesity is a known risk factor 
for diabetes (35,36), depression (37), and osteoarthritis (38–40). Where shared risk factors exist 
(and are modifiable), targeting these first will have the largest impact on an individual’s risk of 
disease overall. In patients at high risk of multiple diseases, it is preferable to target risk factors 
associated with multiple diseases; in this situation, the individual would be subject to fewer 
interventions than if each disease were intervened upon individually, thus reducing intervention 
burden on the patient. 
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2.1.4 Multimorbidity 
Multimorbidity is an extremely common medical condition, especially among older adults (12). 
Although definitions vary, multimorbidity is commonly considered the presence of two or more 
chronic conditions within an individual (41). For example, a patient diagnosed with both asthma 
and diabetes has multimorbidity. Multimorbidity can be contrasted with comorbidity. Both of 
these terms refer to multiple chronic diseases within the same individual; however, when 
examining comorbidities, there is always an index disease that is the primary focus, for which its 
care is modified when additional morbidities are considered. Multimorbidity, on the other hand, 
does not prioritize one disease over another. 
Despite professional agreement that multimorbidity is a pressing health issue (12), there is no 
standard, consistently used definition of multimorbidity (42–44). The European General Practice 
Research Network defines multimorbidity as “any combination of chronic disease with at least 
one other disease (acute or chronic) or bio-psychosocial factor (associated or not) or somatic risk 
factor” (45), without a list of diseases or conditions that should be considered. In contrast, the 
Public Health Agency of Canada considers multimorbidity to be two or more of the following 
diseases within the same individual: heart disease, stroke, cancer, asthma, COPD, DM, arthritis, 
Alzheimer’s or other dementia, mood disorder (depression), and anxiety (29). A recent 
systematic review by Fortin et al. examined the impact of including various numbers of diseases 
in a definition for multimorbidity on the prevalence of multimorbidity (42). Findings of this 
systematic review demonstrated that inclusion of at least 12 chronic conditions in the definition 
of multimorbidity resulted in stable prevalence estimates; including more conditions in the 
definition did not significantly alter the prevalence estimates. Fortin et al. suggest including the 
12 most prevalent chronic conditions in a definition of multimorbidity.  
Prevalence estimates in the literature are inconsistent due to varying definitions of 
multimorbidity; however, estimates of multimorbidity prevalence in older adults range from 55 
to 98% (12). According to the Public Health Agency of Canada definition of multimorbidity, the 
prevalence of multimorbidity in 2014 was 14.8% in Canadians aged 20 and older.  
Multimorbidity has impacts on both patients and their HCPs. This complex condition that 
imposes a huge burden on patients has been shown to reduce health-related quality of life, limit 
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activities of daily living, and decrease self-rated health (46,47). An inverse relationship has been 
found between multimorbidity and health-related quality of life; as the number of multimorbid 
diseases increases, health-related quality of life has been found to decrease (48). Issues such as 
polypharmacy, fragmentation of care, and conflicting or competing health care recommendations 
may be faced by patients with multimorbidity (12), making treatment of these individuals 
complicated. The economic burden of multimorbidity is massive; in 2009, nearly 80% of health 
care costs in Canada were due to individuals with multimorbidity (49). Wikström et al (50) 
examined risk factors specifically for multimorbidity. They found that smoking, physical 
activity, and BMI were significant contributors to risk of multimorbidity development. 
Additionally, systolic blood pressure and low education contributed to risk of multimorbidity 
among men. Dhalwani et al (51) examined the impact of physical activity on development of 
multimorbidity among an older English population; they found a dose-response relationship 
between levels of physical activity and multimorbidity: for those at higher levels of physical 
activity, fewer developed multimorbidity. Dankel et al. (19) examined the impact of muscle-
strengthening activities on multimorbidity risk. Those who participated in the muscle-
strengthening activities had 26% lower odds of developing multimorbidity. These studies 
demonstrate the importance of physical activity for the prevention of multimorbidity. Recently, 
there has been a focus on developing strategies to prevent multimorbidity as health policy 
makers and health care providers recognize the importance of multimorbidity (52). In 2015, the 
Public Health Agency of Canada published a report that stressed the importance of addressing 
chronic disease from a comprehensive, holistic approach, including consideration of 
multimorbidity, rather than a single-disease-centred approach (53). 
Three chronic diseases commonly associated with multimorbidity are diabetes mellitus, 
hypertension, and osteoarthritis. 
2.1.5 Diabetes Mellitus 
Diabetes mellitus (DM) is a group of metabolic disorders characterized by elevated blood 
glucose levels over prolonged periods (54). DM comprises two main conditions: type 1 DM, in 
which the pancreas is not able to produce enough insulin and type 2 DM, in which the pancreas 
produces insulin but the body’s cells fail to respond properly. As type 2 DM progresses, failure 
to produce insulin may also develop (55). Type 1 DM, traditionally termed juvenile diabetes as 
   
 
   
 
9 
its onset typically occurs before adulthood, comprises approximately 10% of cases of DM (56). 
The most common cause of type 1 DM is an autoimmune attack on the insulin-producing beta 
cells of the pancreatic islets, resulting in insulin deficiency (57). Type 2 DM is the more common 
of the two, comprising approximately 90% of cases of DM (56). Its onset is typically in 
adulthood; however, a growing proportion of younger individuals are developing type 2 DM 
(58). This is likely due to the increase in risk factors for DM, such as obesity, lack of physical 
activity, and poor diet, in youth. 
Based on national survey data, the population prevalence of DM (both type 1 and type 2) is 
roughly 9.8% (29). Based on a Canadian study using electronic medical record data conducted 
by Greiver et al., the prevalence within primary care patients was 8.2% (59). When corrected 
using a corrected yearly contact group denominator, the population prevalence of DM was 7.6% 
(59).  
Patients with type 1 DM must manage their glucose levels using insulin injections; this requires 
monitoring of blood glucose levels using repeated blood tests and administration of insulin 
injections (60). Patients with type 2 DM do not always require insulin. Lifestyle changes, such as 
proper diet and exercise, and medications (e.g., metformin), are used to manage patients with 
type 2 DM (60). Insulin injections may be added to treatment when the disease has progressed; 
however, most individuals do not initially require insulin (55). 
Complications of DM are the same for both type 1 and type 2 DM and are minimized through 
proper control of glucose levels (61,62). DM leads to both microangiopathy and 
macroangiopathy, often resulting in severe complications, both acute and chronic (54). Acute 
complications, such as hypoglycemia, hyperglycemia, and, less commonly, diabetic coma, can 
occur within patients with DM. Chronic complications include diabetic nephropathy (i.e., 
damage to the kidney that can lead to chronic kidney failure); diabetic retinopathy (i.e., growth 
of poor-quality blood vessels and swelling that can result in vision loss or blindness); diabetic 
cardiomyopathy (i.e., damage to the heart muscle that can lead to heart failure); cardiovascular 
disease; and foot ulcers.  
Type 1 DM is currently not preventable (60); however, type 2 DM may be delayed or prevented 
through the modification of risk factors (60). Non-modifiable risk factors for type 2 DM include 
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older age (36,63); male sex (36); polycystic ovarian syndrome (PCOS) (64); psychiatric 
disorders such as schizophrenia (65,66), depression (67), bipolar disorder (66,68); family history 
of type 2 diabetes (36); air pollution (69); and low socioeconomic status (70). Modifiable risk 
factors for type 2 diabetes include obesity (35,36,63,70), waist circumference, lipid disorders 
(36), hypertension (36,63), smoking (36,63), stress (36), and low physical activity (70). The 
effectiveness of diet-and-exercise programs in reducing diabetes incidence through weight 
reduction and regular physical activity has been demonstrated in many randomized controlled 
trials (RCTs) (71–73). Bariatric surgery to facilitate weight loss has shown promise in preventing 
type 2 DM development (74). Several pharmacotherapies have been investigated for type 2 DM 
prevention. Metformin has been shown to significantly reduce risk of developing diabetes (71), 
even after medication discontinuation (75,76). Other medications have been investigated, 
including thiazolidinediones such as troglitazone (77), rosiglitazone (78), ramipril (79), and 
pioglitazone (80); alpha-glucosidase inhibitors (81); orlistat (82); and incretin-based therapies 
such as liraglutide (83); however, results remain indefinitive, limiting their use. Clinical practice 
guidelines published by Diabetes Canada (formerly the Canadian Diabetes Association) (84) 
recommend reduction of type 2 DM risk through a structured lifestyle modification program, 
including weight loss, physical activity and pharmacological therapy with metformin or 
acarbose, in patients with impaired glucose tolerance.  
2.1.6 Hypertension 
Hypertension is a condition in which blood pressure in the arteries is consistently elevated (85). 
Hypertension due to some identifiable cause, such as pregnancy, polycystic kidney disease, or 
medication, is referred to as “secondary hypertension”; this form of hypertension comprises only 
5-10% of cases (86). Hypertension due to unknown causes is referred to as primary (or essential) 
hypertension, constituting the remaining 90-95% of cases (86,87). Hypertension does not usually 
cause symptoms; however, chronic high blood pressure is a known risk factor for cardiovascular 
disease, stroke, vision loss, and chronic kidney disease (85,88). Reduction of blood pressure 
through lifestyle modifications and medications reduces risk of complications (85,88). Patients 
diagnosed with hypertension are encouraged to reduce their blood pressure to target blood 
pressure recommended by various expert groups (89); the Canadian Hypertension Education 
Program (90) recommends a target blood pressure of less than 140/90 for the general population. 
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Based on the Canadian Health Measures Survey (CHMS), the national prevalence of 
hypertension in Canada was 22.6% in the years 2012-2013 (91). Based on a Canadian study 
using electronic medical record data conducted by Godwin et al., 22.8% of a primary care 
population had a diagnosis of hypertension as of 2012 (92). Of this primary care population, 
most patients (80%) diagnosed with hypertension were able to reach target blood pressure levels. 
As hypertension does not result in symptoms (85), the burden of the disease itself on patients is 
low. However, hypertension has a large impact on individuals when considering its long-term 
complications; CVD, stroke, vision loss, and chronic kidney disease all have severe impacts on 
an individual’s well-being.  
Non-modifiable risk factors for hypertension include older age (93), diabetes (93,94), kidney 
disease (95), and sleep apnea (96). Modifiable risk factors include obesity (93,94), smoking (93), 
stress (97), tricyclic antidepressant use (98), and high salt intake (93,99). 
Primary prevention of hypertension focuses on modification of its risk factors. For example, the 
DASH diet (Dietary approaches to stop hypertension) (100) aims to reduce salt consumption 
through modification of diet. Physical activity is commonly recommended to reduce risk of 
hypertension; many epidemiologic studies have demonstrated a consistent dose-response 
relationship between physical activity and development of hypertension, in which higher levels 
of physical activity were associated with lower rates of hypertension (101). Additionally, weight 
loss, even modest, has been shown to decrease risk of hypertension (102). Indeed, the Canadian 
Hypertension Education Program recommends the following (103) for the prevention of 
hypertension: regular physical activity; maintenance of a healthy body weight; alcohol 
consumption within the Canadian low-risk drinking guidelines (104); maintenance of the DASH 
diet (100); reduction of sodium consumption; and stress management. 
2.1.7 Osteoarthritis 
Osteoarthritis is a degenerative joint disease characterized by the breakdown of joint cartilage 
and the underlying bone (105). Symptoms of osteoarthritis most commonly include joint pain 
and stiffness (105). As the disease progresses, the severity of pain and stiffness increases, and 
movement patterns are typically affected. The most commonly affected joints are those of the 
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hands, neck, lower back, hips, and knees. Typical treatment of osteoarthritis involves lifestyle 
modification and medications (106–108). Weight loss has been shown to reduce pain and 
stiffness and improve function of the joint (109). Medications, such as non-steroidal anti-
inflammatory drugs, are used for treatment of pain. In cases where the impact of osteoarthritis 
symptoms are severe and conservative forms of treatment are ineffective, joint replacement 
surgery may be recommended, in which the affected joint is replaced with an artificial joint. 
Replacement of hip and knee joints have been shown to be clinically (110,111) and cost effective 
(112,113). 
The population-based prevalence of osteoarthritis was estimated to be 13.0% in Canadians aged 
20 and older (28). Based on a study in Canada using electronic medical record data conducted by 
Birtwhistle et al., the prevalence of osteoarthritis within the primary care population was 14.2% 
in 2012 (114).  
The impact of osteoarthritis on individuals living with the disease is dependent upon the joint(s) 
affected and the progression of disease. Osteoarthritis of the knee and hip can limit activities 
such as running or walking, whereas osteoarthritis of the hand joints can impede activities such 
as writing or typing. Degree of disease progression and an individual’s ability to manage 
symptoms affects how activities are affected.  
Efforts surrounding osteoarthritis management typically focus on treatment of symptoms, rather 
than disease prevention. This is likely due to its slow, progressive nature with no clear point of 
disease onset. Non-modifiable risk factors for osteoarthritis include leg length inequality (115), 
older age (39,40,116–118), female sex (39,40,116,117), family history of osteoarthritis (116), 
and osteoporosis (39). The modifiable risk factors for osteoarthritis are obesity (38–40,116–119), 
previous joint injury (38,40,117,119), and physically intensive occupations (116). Suggested 
osteoarthritis prevention efforts concentrate on obesity. For example, a diet-and-exercise 
program aimed at weight reduction was found to be suggestive of a reduction in the incidence of 
knee osteoarthritis (120). There is growing interest in preventing osteoarthritis through the 
implementation of joint injury prevention programs (121). To date, there are no established 
guidelines pertaining to the prevention of osteoarthritis. 
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2.2 Prognostic Predictive Models 
2.2.1 Overview 
Prognostic predictive models can be used to estimate the risk of developing a chronic disease. In 
particular, the objective of prognostic predictive models (PPMs) is to inform patients and care 
providers about patient risk, and thereby motivate the use of interventions that prevent future 
disease development. There are several levels of disease prevention, each used at different stages 
of disease progression. Primary prevention describes the efforts taken prior to disease 
development to reduce risk of future disease development (122,123). Common primary 
prevention interventions include eating a healthy diet, quitting smoking, or exercising regularly. 
Secondary prevention describes diagnostic efforts after disease onset but prior to clinical 
manifestations (symptoms) of disease to detect the initial stages of disease, allowing for early 
treatment; for example, breast cancer screening is done to detect the disease earlier, when 
treatments are more effective (122,124). Tertiary prevention describes the actions taken to reduce 
the impact and ease the burden of an on-going disease (122,125). One example of a tertiary 
prevention intervention is physiotherapy following a joint injury to improve joint function. PPMs 
are one tool used to support the primary prevention of disease. 
Traditional primary prevention interventions include risk management. Risk management refers 
to the forecasting and evaluation of patient risk and practices aimed at reducing this risk (126–
128). Individual risk factor management is a specific type of risk management. According to this 
strategy, risk factors for chronic disease are individually assessed through risk assessments and 
subsequently intervened upon; however, recent research has demonstrated that risk assessments 
that examine a patient’s global risk of disease by considering multiple risk factors 
simultaneously have been more effective in risk reduction (129). A patient’s global risk takes 
into account the impact of multiple risk factors to estimate the risk that the patient will develop 
disease within a given time period (130). One method of estimating a patient’s global risk of 
disease is through the use of PPMs. 
Previous methods of risk estimation have relied upon anecdotal evidence and professional 
opinion of the practitioner and often vary between practitioners. PPMs represent an objective, 
evidence-based method of assessing an individual's risk of future disease development using 
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multiple risk factors (131). These models present estimated risk in the form of a risk score, 
usually a numeric value where a greater value denotes greater risk (132). Alternatively, 
individuals are assigned to categories corresponding to varying degrees of risk. Common PPMs 
include the Framingham Risk Score for cardiovascular disease (9) and EuroScore to estimate risk 
of death after a heart operation (133). 
Multivariable statistical methods are used in PPMs. A PPM estimates the risk of some outcome 
(future development of disease) based on a set of covariates (characteristics shown to indicate 
risk, or risk indicators). This is distinct from past risk estimation methods where individual risk 
factors were assessed independently then intervened upon. Compared to the use of a single 
predictor, the use of multiple predictors allows for more accurate estimation of a patient’s risk 
(5), as multiple risk factors commonly coexist within an individual (130). Interaction between 
risk factors occurs when the joint effect on risk is greater than what would be expected by adding 
or multiplying the effects of each risk factor; these interactions can be modelled by PPMs by 
including an interaction term in the model (134). Characteristics of the patient, provider, or 
practice can be included as covariates in the model. Potential patient level covariates include 
patient demographics, family history, lifestyle factors, medical conditions, and genetic factors 
(3). Potential provider level covariates include specialization (if any), years in practice, and 
additional certifications. Potential practice level covariates include rurality, number of 
practitioners, and geographic location. Inclusion of characteristics from multiple levels requires 
the use of advanced methods such as multilevel modelling (135).  
PPMs are distinct from etiologic research. The focus of prognostic research is to predict some 
outcome, whereas etiologic research aims to identify the cause of some outcome (136). Both 
prognostic and etiologic research use multivariable approaches; however, in etiologic research, 
the goal is to isolate the main causal effect of some exposure by adjusting for the effects of other 
confounding factors (136). In contrast, prognostic research uses a multivariable approach to 
estimate risk of an outcome as accurately as possible by including as much potentially predictive 
information as possible (5). As such, covariates included in a prognostic model do not have to be 
causally related to the outcome (and are often not). Risk management practices can then be used 
to minimize the risk among high-risk patients by intervening on factors that are known to be 
causal. 
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2.2.2 Conceptual Model 
Two theories exist that drive the use of PPMs, one at the individual level and another at the 
population level. At the individual level, the theory driving the use of PPMs posits that 
knowledge of disease course enables patients and practitioners to make informed decisions to 
avoid or deter the development of disease (5). At the population level, the use of PPMs is driven 
by the need for identification of patients at high-risk of disease, enabling targeted interventions 
aimed at reducing risk within these patients (5). The following conceptual model describes the 
process of risk estimation via PPMs, from both the individual and population perspectives. 
 
Figure 1: Conceptual Model for Risk Assessment 
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The four stages of risk assessment outlined in the conceptual model above will be discussed 
below. 
2.2.2.1 Stage 1: Use of Prognostic Predictive Models 
Risk assessments, which commonly include a PPM, can occur in two ways. In the first, either the 
patient or PCP is concerned about risk of future morbidity and the PCP actively performs a risk 
assessment. In this case, there must be some initiation or interest in risk assessment by either the 
patient or PCP. Alternatively, risk assessments can run passively in the background, assessing all 
patients’ risks, and send an alert when a patient is classified as high-risk. In this case, the risk 
estimation model is run regardless of patient or PCP concern about future morbidity. Integration 
of risk assessments into electronic medical record (EMR) systems facilitates both these 
strategies, as tools within an EMR are easily accessible to the PCP and are able to run in the 
background of the EMR. Building these tools into EMRs results in simple incorporation into 
clinical workflow to offer real-time recommendations. 
2.2.2.2 Stages 2 & 3: Change in Provider and Patient Behaviour 
PPMs can be used in primary care to inform PCP decision making regarding risk reduction. Most 
often PPMs are used as a part of a risk assessment. Studies examining the use and impact of 
PPMs in primary care in Canada are rare; most PPM studies focus on the development or 
validation of models, but do not evaluate how current models are used (137). However, many 
Canadian guidelines advocate for the use of risk assessments. The Canadian Cardiovascular 
Society recommends cardiovascular risk assessment using every 5 years for men and women 
between ages 40 and 75 using PPMs such as the modified Framingham Risk Score or 
Cardiovascular Life Expectancy Model (138). The results of these risk assessments are used to 
inform decisions regarding interventions to reduce risk of cardiovascular events. Other examples 
include the 2010 Clinical Practice Guidelines from Osteoporosis Canada, which recommends 
osteoporosis and fracture risk assessment for individuals over age 50 who have experienced a 
fragility fracture or who have a history of falls (139). These risk assessments can inform 
interventions such as exercise and prevention of falls, calcium and vitamin D supplementation, 
or pharmacologic therapy.  
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Many factors limit the use of PPMs in clinical practice. A qualitative study examined barriers 
cited by PCPs limiting their use of PPMs in clinical practice including lack of lifestyle 
recommendations, legal and regulatory constraints, and lack of accuracy of risk scores (140). 
PCPs felt that predictive models focused more on non-modifiable risk factors, such as age, thus 
limiting their ability to give recommendations on more relevant, modifiable risk factors such as 
lifestyle. PCPs also expressed concerns over the current regulations that did not place a focus on 
disease prevention; no remuneration exists for time spent on risk assessment and prevention. 
PCPs feared that the estimated risk scores were not an accurate representation of individual 
patient’s risks, and thus were less likely to use the PPM. 
2.2.2.3 Stage 4: Change in Patient Outcomes 
Similar to studies looking at their use, few studies in Canada have examined the impact of PPMs 
on clinical outcomes, such as impact on risk, disease incidence, or physician behaviours; 
however, some studies exist examining their use. The National Health Service (NHS) Health 
Check is a health check-up for adults that includes a CVD risk assessment (141). All adults in 
England between the ages 40 and 74 without a pre-existing condition are invited by their PCP or 
local authority for a free NHS Health Check every 5 years in an effort to reduce risk of chronic 
disease. The introduction of the NHS Health Check was shown to be associated with significant 
reductions in CVD risk, as well as improvements in statin prescriptions (142). The 
Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes 
Mellitus (RAMP-DM) in Hong Kong had similarly promising results, finding that a risk 
assessment and management program (which included a risk assessment component) was 
associated with fewer cardiovascular complications and lower all-cause mortality after 3 years 
(143). In contrast, a systematic review conducted by Brindle et al. described several studies that 
observed no impact from PPM risk assessment on the observed outcomes, which included 
predicted risk of CVD, fatal or non-fatal CVD events, risk factor levels, prescription of risk-
reducing drugs, and changes in health-related behaviour (144); however, this review frequently 
noted that the PPM’s use by PCPs was either poorly recorded or not recorded at all. Indeed, it is 
unclear whether the lack of impact was due to the efficacy of the PPM or the lack of use by the 
physician. 
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2.2.3 Settings of Prognostic Predictive Model Use 
Primary care is the first point of patient contact where, most often, patients are seen prior to 
disease development; once patients reach secondary or tertiary levels of care they have already 
developed disease, thus prognostic risk estimation is of little value in these clinical settings. For 
this reason, primary care is an ideal setting for targeted primary prevention efforts, including the 
use of PPMs. PPMs can be used to inform the PCP decision-making process surrounding risk 
management, such as whether or not to recommend risk lowering interventions. Many guidelines 
recommend the use PPMs to detect high-risk individuals for primary prevention efforts 
(145,146).  One common PPM used in primary care is the Framingham model for cardiovascular 
disease (CVD) (147), which estimates a patient’s risk of developing CVD in the next 10 years 
based on risk factors including age, sex, cholesterol levels, and smoking status. PCP decisions 
such as whether or not to prescribe statins or to recommend lifestyle changes are informed by 
this model.  
Additionally, PPMs are commonly used as online tools to deliver risk estimates to the general 
population over the internet (148,149). This method allows a larger population, beyond primary 
care patients, to access personalized risk estimates in a convenient manner and receive 
recommendations on ways to reduce risk. Online risk assessments are based on established PPMs 
that have been empirically developed and validated; however, these models are sometimes 
modified to substitute covariates that are not commonly known by individuals. For example, 
personal blood cholesterol within the Framingham cardiovascular risk assessment may be 
replaced with an average value as most individuals will not likely know their blood cholesterol 
levels off-hand. Given the current status of PPM use in primary care, online risk assessments are 
able to reach a much greater proportion of the population. The deployment of online PPMs aims 
to reduce the overall incidence of disease within the community by informing individuals of their 
personal risk and subsequently recommending risk reducing interventions. 
2.2.4 Prognostic Predictive Model Development 
The development of a PPM is a complex process involving risk factor identification, data 
processing, and statistical analysis. For a complete description of the processes involved in PPM 
development, see the Transparent Reporting of a Multivariable Prediction Model for Individual 
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Prognosis or Diagnosis (TRIPOD) Statement (150). Ideally, there are three stages in prognostic 
research: model development, validation, and clinical impact evaluation (5).  
Model development requires knowledge of the relevant risk factors for the disease of interest; a 
review of the relevant literature will reveal risk factors for the disease. Also required for model 
development is a dataset from which to build the model. When developing a PPM, it is optimal 
to use a prospective cohort study conducted specifically to collect data to inform the PPM 
development (151). However, due to the high costs associated with primary data collection, 
development of PPMs may make use of data previously collected (retrospective data). Results 
from retrospective data are more prone to bias as predictor and outcome information is less 
systematically recorded (1). Common sources of retrospective data include previous 
observational studies, randomized controlled trials, and health administrative data (6,152,153).  
PPMs are constructed using statistical techniques, commonly regression, to estimate risk of 
disease development in the future (2). The type of regression used is primarily dependent on the 
type of outcome that is to be predicted. For example, when continuous outcomes are to be 
predicted, linear regression (154) is commonly used; when binary (“dichotomous” or yes/no) 
outcomes are to be predicted, logistic regression (155) is commonly used; or when time-to-event 
outcomes are to be predicted, Cox regression (156) is commonly used. Each of these methods 
posit a (possibly transformed) linear relationship between the covariates and the outcome and are 
each considered Generalized Linear Models. Advanced methods, such as Generalized Additive 
Models (157), can be used to model more complex, non-linear relationships between covariates 
and outcomes. These methods offer the advantage of accounting for non-linearity between the 
covariates and the outcome, better modelling the relationships in the data; however, they 
sacrifice some interpretability of the model, as such models are often more difficult to 
understand. Disease status is generally considered a binary outcome; a patient either has the 
disease or they do not. For this reason, logistic regression or survival analysis methods are most 
commonly used to model disease outcome data for PPMs. Other non-regression methods exist to 
predict future disease development; these include decision trees (158), where patients pass 
through a series of yes/no questions to eventually classify their risk of disease development, or k-
nearest neighbours (159), where a patient is classified according to the risk corresponding to 
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those most similar to them. While these models are sometimes more easily interpreted, they are 
not as frequently used as regression methods.  
Following the development of the model, it must be validated to assess its accuracy. Model 
validation consists of internal and external validation (160). Internal validation is performed on 
data from the same source used to construct the model, either using a held-out portion of the data 
or methods such as cross validation (161) or bootstrapping (162). External validation applies the 
model to a different population that is similar to determine its accuracy (163). At a minimum, 
validation looks at discrimination and calibration.  Discrimination is the ability to correctly 
assign higher risk to a patient who ultimately experiences the outcome compared to the patient 
who does not (4). Discrimination is commonly assessed via the c-statistic or an ROC curve 
(164). Calibration is a measure of how well a model fits the data (4); this describes how well the 
risk estimates the true proportion of patients that will develop disease. For patients assigned a 
given risk (probability), approximately the same proportion of patients should actually go on to 
develop disease in a model with high calibration. This can be assessed using the Hosmer-
Lemeshow test (155) or a calibration plot; however, the Hosmer-Lemeshow test has been shown 
to be over-sensitive when dealing with large datasets (3). 
The final step in the development of a PPM is to assess its clinical impact (137). Rather than 
simply assessing performance of the model (i.e. how well the model predicts the outcome), this 
stage assesses the model’s impact on physician practices, patient care, and patient outcomes. 
Examples of impacts include modification of physician behaviours, such as prescribing patterns; 
modification of patient risk; and change in disease incidence. Most PPMs are internally validated 
at a minimum; however, few are validated on an external dataset, and even fewer have had their 
clinical impact assessed (165). 
2.2.5 Prognostic Predictive Model for Multiple Diseases 
Traditional PPMs estimate risk for individual diseases; however, many chronic diseases have 
been found to cluster in the same individuals, whether they occurred at the same time or 
accumulated over a period of time (20–22). As a result, patients are often burdened by multiple 
diseases. PPMs for multiple diseases have been poorly studied in the literature. In order to enable 
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the development of PPMs for multiple diseases, advanced statistical methodologies and data that 
are numerous and highly descriptive, such as electronic medical record data, are required.  
2.3 Methodologies for Multiple Disease Risk Estimation 
To understand the methodologies required for the estimation of multiple disease risk, an 
understanding of the concepts related to joint distributions and dependence are first required. 
Subsequently, an overview of one method for the estimation of multiple disease risk is presented. 
2.3.1 Joint and Marginal Distribution of Binary Random Variables 
Consider two random variables 𝑋𝑑 and 𝑋ℎ, each of which can take the value 0 or 1. Let 𝑋𝑑 = 1 
represent the event that an individual develops diabetes within a 5-year period and 𝑋𝑑 = 0 
represent no development of diabetes within that interval. Let 𝑋ℎ be the analogous random 
variable, but for hypertension. 
After waiting for the 5-year period, the values (𝑥𝑑, 𝑥ℎ) are observed, which are the realizations 
of the two random variables. There are four possibilities: (0,0) if the patient develops neither 
disease; (0,1) if the patient develops hypertension but not diabetes; (1,0) if the patient develops 
diabetes but not hypertension; and (1,1) if the patient develops both diseases. Note that these four 
possibilities are mutually exclusive and exhaustive – the patient must fall into exactly one of 
these categories. 
By observing many patients, the probability of observing any one of these realizations may be 
estimated. The four probabilities give the joint distribution of the two random variables. (Note, 
however, that since they sum to one, if three probabilities are known we can compute the fourth.) 
A marginal distribution refers to the distribution of one disease without consideration of the 
other; each variable has a marginal distribution. In this example, one marginal distribution would 
describe the probabilities of developing diabetes without considering hypertension while the 
other would describe the probability of developing hypertension without considering diabetes. 
These can be computed by marginalizing out the other variable – for example, the marginal 
probability of developing diabetes would be the probability of observing (1,0) plus the 
probability of observing (1,1). 
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Suppose the development of diabetes and the development of hypertension were truly 
independent of each other; that is, the occurrence of diabetes was not related to the occurrence of 
hypertension. In this case, the joint distribution of diabetes and hypertension would be no 
different from what would be expected by multiplying the marginal probabilities of diabetes and 
hypertension. This is the null hypothesis commonly used when analyzing contingency tables 
with the 𝜒2 test or Fisher’s exact test.  
The 𝜒2 test evaluates the null hypothesis that each disease is independent of the other by 
comparing the expected and observed disease frequencies (166). When sample sizes are small, 
Fisher's exact test should be used (166). 
The same methods can be applied to the analysis of three diseases. In this case, the frequencies 
of each combination of the three diseases are considered. Again, the 𝜒2 test and Fisher's exact 
test can be used to evaluate the null hypothesis that each disease is independent of the others.  
Dependence among the variables describing disease development may be observed in a 
population because they have common risk factors. For example, higher BMI may be associated 
with development of diabetes and development of hypertension. If a contingency table is 
analyzed using a sufficiently large population with a range of BMIs, dependence will be detected 
between 𝑋𝑑 and 𝑋ℎ. However, it may be that for any given value of BMI (or perhaps a small 
range) the development of the two diseases happens independently. Assessment of dependence 
after stratifying on a risk factor can be achieved by the Cochrane-Mantel-Haenszel test. The 
Cochrane-Mantel-Haenszel test accounts for confounding variables through stratification into 
discrete categories; however, this method does not directly make use of continuous variables. 
Instead, a two-stage approach to model the joint distribution of disease development can be used. 
This approach first uses univariate multivariable logistic regression to model the marginal 
distribution of development of each disease and then uses a copula to combine the marginal 
distributions together into a joint distribution. This approach has the ability to 1) account for 
more than two diseases at a time; 2) adjust for both categorical and continuous variables; and 3) 
ultimately be used in the construction of a predictive model. 
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A copula is a multivariate probability distribution used to describe the non-linear dependence 
between multiple outcomes where each univariate marginal distribution is uniquely defined 
(167,168). Copulas are defined by Sklar’s theorem, which states that every multivariate 
cumulative distribution function of the variables considered can be expressed in terms of their 
univariate marginal distributions and a copula (169). The copula (meaning link in Latin) links the 
univariate marginal distributions together, forming the multivariate joint distribution. 
2.3.2 Univariate Multivariable Logistic Regression 
The first step in constructing a copula is the estimation of univariate multivariable logistic 
regression models. Univariate multivariable logistic regression seeks to understand the 
relationship between multiple covariates and a single binary outcome (univariate: one outcome; 
multivariable: multiple covariates) (155). Univariate logistic regression is based on the logistic 
function, which is used for modelling the probability distribution of binary data as its output only 
takes on values between zero and one due to its S-shape. The logistic function (t) is defined as 
follows: 
𝜎(𝑡) =  
1
1 +  𝑒−𝑡
 
The logistic function applied to a linear function of several explanatory covariates gives a 
logistic regression function. 
𝐹 (𝑥𝑖) =  
1
1+ 𝑒−(𝛽0+𝛽𝑖𝑥𝑖)
=  𝜎(𝛽0 + 𝛽𝑖𝑥𝑖)  
Where 𝛽0 denotes some constant, 𝛽𝑖 denotes some constant(s) by which the explanatory 
variable(s) will be multiplied, and 𝑥𝑖 denotes the explanatory variable(s). Given knowledge of all 
explanatory covariates and estimates ?̂?𝑖 of the coefficients, the probability of experiencing the 
outcome is estimated by 
?̂?(𝑥𝑖) =  
1
1+ 𝑒−(?̂?0+?̂?𝑖𝑥𝑖)
=  𝜎(?̂?0 + ?̂?𝑖𝑥𝑖).  
Odds can be estimated by applying the exponential function. 
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Odds =  𝑒?̂?0+?̂?𝑖𝑥𝑖 
The logistic regression coefficients were estimated using maximum likelihood estimation. 
2.3.3 Copulas 
Once univariate multivariable logistic regression models have been constructed, the copula is 
then constructed, which ties together the univariate models. There exist many copula functions, 
each with its own unique properties that allow it to model different dependence structures. For 
example, the Frank copula (170) exhibits weak dependence in both tails. One of the most 
common classes of copula functions, Archimedean copulas, is described below. 
2.3.3.1 Archimedean copulas 
Archimedean copulas encompass a variety of copula functions that can all be characterized by an 
explicit formula. Archimedean copulas are commonly the preferred method of dependence 
modelling due to their ability to model dependence in arbitrarily high dimensions with a single 
parameter that governs the strength of the dependence (167,168). Archimedean copulas follow 
the structure: 
𝐶(𝑢1, … , 𝑢𝑑; 𝜃) = 𝜓
[−1](𝜓(𝑢1; 𝜃) + ⋯ + 𝜓(𝑢𝑑; 𝜃); 𝜃) 
where θ is a parameter within some parameter space Θ, ψ is the generator function (a function 
unique to the copula used), and 𝜓[−1] is its pseudo-inverse given as: 
𝜓[−1](𝑡; 𝜃) = {
𝜓−1(𝑡; 𝜃) if 0 ≤ 𝑡 ≤ 𝜓(0; 𝜃)
0 if 𝜓(0; 𝜃) ≤ 𝑡 ≤ ∞.
 
As seen, the generator function determines the copula function; θ must be estimated based on the 
dependence that exists between variables. Larger values of θ correspond to larger amounts of 
dependence between diseases. 
 For example, the generator function for the Gumbel copula is (171): 
(− log(𝑡))𝜃 
which gives the following function: 
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𝐶𝜃(𝑢, 𝑣) = exp [−((− log(𝑢))
𝜃 + (− log(𝑣))𝜃)
1
𝜃] 
where θ  [1, ) 
The Gumbel copula (171) is an asymmetric copula that exhibits greater dependence in the 
positive tail than in the negative tail. Other examples include the Frank copula (170), which is a 
symmetric copula that is used to model weak dependence and the Clayton copula (172), which is 
an asymmetric copula function that exhibits greater dependence in the negative tail than in the 
positive. Many other copula functions exist, each with its own unique properties. 
Copulas have been used commonly in finance, where financial distributions often are non-
normal. For example, copulas have been used extensively in the area of financial risk 
management (54). During a recession, investors who hold positions in riskier assets, such as real 
estate, may move their investments into safer alternatives, such as cash or bonds. This trend 
results in an asymmetric distribution, where correlations across equities are greater in the 
downward direction compared to the upward direction. Copulas aid by modelling the marginal 
distributions separately from the dependence structure. In this example, marginal models can 
describe the behaviour of individual investors. However, the actions of one investor are not 
independent of those of other investors; thus, copulas allow the modelling of the behaviour of 
investors while considering the actions of other investors. Copulas have also been used in the 
areas of engineering (55), neuroscience (56,57), and climate and weather research (58,59). 
2.4 Electronic Medical Records 
As mentioned, one potential source of data for the development of a PPM for multiple diseases is 
EMR data. Explained in greater detail below, these data sources contain the medical records, 
including diagnoses, prescriptions, treatments and laboratory results, of thousands of patients that 
may enable the estimation of the risk of multiple diseases. 
2.4.1 Overview 
Electronic medical records (EMRs) are software programs used to store patient information 
electronically. Traditionally, patient information has been stored in paper records; however, there 
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has been a shift from using paper records for this purpose to using EMRs (173). The goal of an 
EMR is to support the delivery of quality care by providing accessible and structured storage of 
information. These digital records contain individual patient information describing 
demographics, medical history, medications, allergies, laboratory test results, radiology images, 
vital signs, patient characteristics such as height and weight, risk factor information, and billing 
information (174). 
Data are stored within an EMR in a variety of ways. Data can be stored in a highly structured 
manner, such as pick-lists or drop-down menus, or highly unstructured manner, such as free-text. 
For example, disease information such as a diagnosis of diabetes may be included in the EMR as 
an entry in the billing table or problem list with the corresponding International Classification of 
Disease (ICD) code. Alternatively, a diagnosis of diabetes could simply be noted in the free-text 
narrative portion. Indeed, there are often multiple ways to store the same information within the 
EMR (175);  thus, data of interest may be found in multiple locations within the EMR. All data 
within the record have an associated date and time, allowing PCPs to look back in the record to 
observe changes over time. 
EMRs support many functions beyond the mere storage and retrieval of information, including 
billing services, appointment scheduling, referral services, laboratory test requisitions, and 
medication prescriptions (173,174). Furthermore, EMRs often support other functions known as 
decision support tools. Examples of these tools include medication interaction tools, which alert 
PCPs to potential interactions between medications when prescribing (176); clinical guidelines, 
which provide easy access to evidence-based guidelines (177); and risk assessments, which 
estimate a patient’s risk of experiencing some future outcome (178).  
EMRs are commonly developed and maintained by private vendors; however, open source 
options, such as OSCAR (179), exist. Canada does not have one single EMR software program, 
as health care is managed at the provincial and territorial levels. Instead, several EMR vendors 
exist, each with their own EMR software, competing for PCP and hospital business. As a result, 
there is no single repository containing the health records of all Canadians. 
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2.4.2 Uptake of EMRs in Canada 
The current rate of EMR use in Canada is more than twice that of 2009; thirty seven percent of 
PCPs used an EMR to store patient information in 2009, whereas 73% of PCPs reported doing so 
in 2015 (180). While this recent increase in uptake is promising, Canada still falls below the 
international average by 15% (180). Provincial rates were found to be quite variable, with 
Alberta at 85% adoption and New Brunswick at 40% adoption (180). Given their level of use 
and potential to support clinical care, the extent to which EMRs are being utilized has been 
examined. Only 41% of Canadian PCPs use EMRs to support quality of care decisions, such as 
drug interaction tools or reminders for regular care or screening tests, compared to 58% 
internationally (180).  
2.4.3 Use of EMRs for Research Purposes 
EMRs represent a rich source of information describing a patient’s health and health care. EMR 
databases can be linked together to form large repositories of patient information that allow for 
health surveillance to inform clinical and epidemiological research, public health interventions, 
health care planning, and quality assurance. For example, the Canadian Primary Care Sentinel 
Surveillance Network (CPCSSN) is a collection of EMR databases from across Canada that 
contains primary care information on more than 1.5 million patients (181). This database has 
been used for surveillance of chronic diseases including hypertension (92), depression (182), and 
diabetes (59). Information are only recorded in an EMR where deemed clinically relevant by the 
EMR user; information such as physical activity, occupation, ethnicity, family history or other 
characteristics that may be important for research purposes are often not noted in EMRs. 
However, an EMR is a great source of population-level data pertaining to patient characteristics 
including diagnoses, laboratory results, medication prescriptions, and referral patterns. 
The form that data are recorded in the database greatly impacts its utility for research purposes. 
Data are readily analyzed when stored in a structured form that arises from the use of drop-down 
boxes or pick-lists. When data are stored in the form of a free-text narrative, methods such as 
natural language processing (183) must be used to extract information from the data. One 
suggested method of improving the usability of EMR databases for research is to encourage 
PCPs to engage in consistent and accurate coding of patient information (184).  
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EMR data only describe the population receiving primary care, not necessarily the general 
population. A study looking at the representativeness of the CPCSSN national database found 
that, compared to data from the 2011 census, CPCSSN patients were somewhat representative of 
the Canadian population (185). CPCSSN patients were roughly 4 years older on average and less 
likely to be male, making it is necessary to adjust for age and sex to generalize results based on 
CPCSSN data to the general population. When applying EMR data to a primary care population, 
no adjustment is necessary. 
EMR data are limited by their use of diagnostic codes as proxies for health events, such as 
disease development. For a symptom or disease to be successfully captured within an EMR, the 
patient or PCP must recognize and report the symptom or disease; subsequently, the practitioner 
must know the proper code and record this in the EMR. Any break in this stream of events will 
result in failure to capture the information. This has implications for research using EMR data, 
where the absence of a diagnostic code is often interpreted as the absence of disease. The extent 
to which this impacts results depends on how well diagnoses of disease are recorded in the EMR. 
Diseases with more significant and clearly defined diagnostic features, such as diabetes, are 
better recorded within the EMR (186). The use of diagnostic codes is also problematic as 
diagnostic codes are not always able to fully capture the complexities of chronic diseases.  
Compared to alternative sources of health information, such as health administrative data or 
primary data collection from observational studies, EMR data are both rich and numerous. 
Despite describing the health of the majority of the population in Canada, health administrative 
data are limited by what is captured; for example, only billing codes for the “most responsible 
diagnosis” are stored in health administrative databases (187). EMR databases can be used to 
overcome this limitation as they contain a rich history of patients’ health, including past and 
current diagnoses, medications, laboratory results, and radiographic images (174). In Canada, 
EMR databases do not contain records of the entire population, whereas health administrative 
databases contain data wherever a patient has received care due to the remuneration methods 
employed in Canada; however, the data that are collected in EMR repositories such as CPCSSN 
are often sufficient to allow for analyses at the provincial and national levels (185). Primary data 
collection obtains precisely what patient characteristics are of interest using a consistent method 
or measure; comparatively, EMR data are only collected where clinically relevant and often do 
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not describe the measure used (175). Primary data collection, however, requires significantly 
greater resources when compared to EMR data (188), where the data have been previously 
collected.  
 
 
Table 1: Comparison of Data Sources 
EMR Observational Studies Health Administrative 
Data 
Large sample size Small sample size Large sample size 
Contain all diagnostic 
codes recorded in a single 
encounter 
- Contain only one diagnostic 
code per encounter 
Collect only data deemed 
clinically relevant 
Collect all data of interest Collect only data deemed 
necessary for 
administration/billing 
Measurement method 
unknown 
Data collected using a 
standardized measure 
Measurement method 
unknown 
2.5 Summary 
The current literature demonstrates the need for novel techniques aimed at the prevention of 
chronic disease. In particular, multimorbidity is a pressing concern for which prevention 
techniques remain underdeveloped. Prognostic predictive models present an opportunity for such 
a technique that might allow insight into a patient’s risk of multimorbidity. Such insight might 
allow for targeted interventions aimed at reducing patient risk. EMRs may contain the data 
needed for the development of these models, as these data sources contain health information of 
numerous patients over time. 
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Chapter 3  
3 Methods 
The following chapter describes the development of a prognostic PPM for multiple chronic 
diseases using data from EMRs. Logistic regression and copula modelling were used in model 
development. 
3.1 Data Source 
Data were derived from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) 
database (181). Initially formed in 2008 through funding provided by the Public Health Agency 
of Canada (PHAC), this nation-wide database contains patient information from EMRs of 
primary care practices across Canada (184). The objective of this network is to enable both the 
surveillance of chronic disease and primary care research at a national level. CPCSSN aims to 
accomplish these goals by collecting clinical data that provide insight into the health of 
Canadians from a primary care perspective through clinical and epidemiological research. 
 
Figure 2: CPCSSN Structure 
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The CPCSSN database follows a hierarchical structure: individual patient encounters (visits with 
their PCP) are collected for each patient; these encounters are grouped by patients involved in 
these encounters; which are grouped by the PCP from which they receive care; which are 
grouped by the primary health care (PHC) site in which they practice; which are grouped by the 
network to which they contribute their data; which are then contained within the CPCSSN 
database. Originally involving 7 academic primary care research networks across 4 provinces 
(Newfoundland, Quebec, Ontario, and Alberta) (184), the CPCSSN database now involves 12 
regional networks across 8 provinces and territories. Initial recruitment of practices occurred 
from 2008 to 2010, in which family practices (mostly those associated with academic or 
university sites, as these were more likely to participate in research) were recruited to contribute 
their data to the CPCSSN database. Following this initial period, recruitment expanded to 
include non-academic practices in various settings (urban, suburban, and rural). Past and ongoing 
patient consent was obtained via an opt-out system, in which patients who do not wish for their 
information to be contributed to the database may choose to opt out; all provinces operate under 
this system, except for Quebec, where an opt-in process is mandated by provincial law. Within 
these regional networks are 218 practices. Ontario, as one of the founding and most populated 
provinces, has the greatest number of participating practices. British Columbia and Quebec make 
smaller contributions as British Columbia is a relatively new network and legislative 
requirements in Quebec deter the process. The CPCSSN database contains records from 1189 
PCPs. Data describing the nature of PCP’s practice, such as profession (i.e. physician or nurse 
practitioner) or payment model (e.g. fee-for-service or capacitation), are unavailable for most 
PCPs. CPCSSN contains deidentified records of more than 1.5 million patients, making it the 
largest source of primary care information available in Canada.  
The CPCSSN database is comprised of several data tables containing information pertaining to 
either the practice, provider, patient, or patient encounter. For example, the Billing table contains 
all ICD-9 codes used by the provider to submit a billing claim; these data can be used to identify 
diagnoses made by the provider. Note, however, that providers are limited to one diagnosis per 
patient encounter, thus the diagnosis recorded is known as the most responsible diagnosis. The 
Health Condition table contains additional diagnoses made during an encounter, regardless of 
whether they were billed for; this is congruent with the problem list used in other EMRs. From 
the tables contained within CPCSSN, all structured patient records can be extracted, including 
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patient demographics, billing codes, laboratory results, prescriptions, referrals, risk factor 
information, medical procedures, vaccinations, and allergies. For privacy reasons, the free-text 
narrative where PCPs record their notes is not available in CPCSSN. Tables were linked using an 
identifier unique to each patient. 
Table 2: CPCSSN Data Tables 
Table Name Contents Format Completeness 
Billing Diagnoses ICD-9 Codes - 
Health Condition Diagnoses ICD-9 Codes 
Free text 
- 
Encounter Diagnosis Diagnoses ICD-9 Codes 
Free Text 
- 
Patient Age Numeric 99.8% 
Sex Text 99.9% 
Patient Demographic Occupation Text 5.1% 
Highest education Text 2.0% 
Housing status Text 4.4% 
Forward Sortation Area 
(FSA) 
Text 95.4% 
Language Text 14.1% 
Ethnicity Text 1.0% 
Lab Laboratory results Numeric - 
Exam Examination results Numeric - 
Medication Medication prescriptions Text - 
Family History Reported family history Text - 
Risk Factor Reported risk factors Text - 
Medical Procedure Medical procedures Text - 
Referral Referrals Text - 
Vaccine Vaccines received Text - 
Allergy/Intolerance Allergies and intolerances Text - 
Disease Case Validated cases of disease Text - 
Provider Age Numeric 87.8% 
Sex Text 98.3% 
(Provider) Group Info Group type Text 75.9% 
Payment model Text 3.4% 
Site Province Text 100% 
Due to the volunteer basis of practice recruitment, the CPCSSN database can be seen as a 
convenience sample of primary care patients across Canada. CPCSSN patients are somewhat 
representative of the Canadian general population (185). Provincial-level comparisons are 
appropriate for all included provinces, except for British Columbia and Quebec due to their low 
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participation (185). As of 2013, CPCSSN patients were older and more likely to be female 
compared to the overall Canadian population as reported in census data. Research has 
demonstrated that this trend is typical of primary care (189–191). Compared to practitioners 
responding to the National Physician Survey, CPCSSN practitioners were younger, more likely 
to be female (51.1 vs. 44.0%), and from an academic practice (19.3% vs. 7.8%) (185).  
First, the construction of a PPM requires an understanding of what risk factors are known to 
increase the risk of disease development. Next, a cohort of people whose risk factor status at 
baseline and their subsequent disease outcome are known is needed. From this cohort, 
multivariable models are built to describe the associations between each risk factor and the 
disease outcome. 
3.2 Measures 
3.2.1 Outcome 
The following diseases were predicted simultaneously: diabetes, hypertension, and osteoarthritis. 
These diseases were selected based on several criteria. First, the selected diseases are among the 
most prevalent in Canada (53,192). Previously validated case-detecting algorithms for use with 
EMR data exist for these diseases (described more fully below) (193). These diseases are often 
diagnosed and treated in primary care (54,85,105). Each of these diseases have modifiable risk 
factors, some of which overlap between diseases (35,36,63,70). Finally, expert consultation 
revealed that risk estimations for the selected diseases, in particular their co-occurrence, would 
be clinically useful. In this work, recovery from disease was considered not possible; once a 
patient has one of the diseases, they will always have the disease. 
 Chronic pain and asthma were also among the most prevalent diseases; however, neither have a 
validated case-detecting algorithm.  
One initiative of CPCSSN researchers has been to develop and validate case detecting algorithms 
for several chronic diseases that can be used to identify cases of disease within the database 
(193). In an effort to facilitate quality research, CPCSSN has created disease case-detecting 
algorithms for osteoarthritis, depression, hypertension, diabetes, chronic obstructive pulmonary 
disease (COPD), epilepsy, Parkinson’s disease, and dementia. These case-detecting algorithms 
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are composed of information including ICD-9 codes within the billing or problem list; 
medication prescriptions; laboratory results; or any combination of these elements. Construction 
of the case-detecting algorithms was informed by published evidence and input from both 
primary care and specialist physicians. Subsequently, each disease case-detecting algorithm was 
validated by chart review. Chart review was performed by research assistants blinded to the 
diagnosis assigned by the algorithm. Reviewers determined the absence of disease through 
examination of the entire electronic medical record. Where a reviewer was uncertain, the study 
epidemiologist and a physician from the study team performed a chart review. The ability of the 
case-detecting algorithm to correctly assign diagnoses was assessed by comparing its results to 
those of the chart review, resulting in both sensitivity and specificity statistics. Sensitivity and 
specificity for all diseases were high (Appendix A). In this thesis, diagnoses of diabetes, 
hypertension, and osteoarthritis were identified using the case-detecting algorithms developed by 
CPCSSN researchers.  
The use of validated disease case-detecting algorithms helps ensure that the identification of 
disease cases is accurate. This is especially important as inaccuracy in the identification of the 
disease will decrease a predictive model’s performance due to incorrect estimation of the 
relationships between the predictors and actual disease development. This poor performance 
would not be revealed by internal validation because the data used for validation would be 
subject to the same issue of inaccuracy in disease identification as the data used for constructing 
the model. Often only internal validation is feasible, reinforcing the importance of using a 
validated case-detecting algorithm for the identification of disease cases. However, the 
correctness of predictors is not as crucial, since the main goal of this analysis was not etiologic 
research, but the prediction of future disease development. For example, a diagnosis of 
osteoporosis is a risk factor for osteoarthritis; however, the ICD-9 code used for osteoporosis 
also includes several other bone disorders. Despite this ICD-9 code not being specific to 
osteoporosis, it is still useful as a predictor for osteoarthritis because its presence in patient’s 
EMR was found to be significantly associated with future development of osteoarthritis. 
Accordingly, caution must be taken when making causal inferences from the resulting predictive 
model since the model does not truly describe the impact of an osteoporosis diagnosis on risk of 
osteoarthritis, but rather the impact of the presence of the ICD-9 code. 
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As both predictor and outcome assessment was done by the PCP, blinding did not occur during 
outcome assessment, which may have introduced measurement bias. This issue is present in all 
EMR and health administrative data due to the nature of the data. However, the diseases 
predicted are common conditions with clearly identifiable diagnostic criteria, thus skilled PCPs 
should be able to diagnose cases of disease with a high degree of accuracy, limiting the influence 
of knowledge of predictor status at baseline on this assessment, and in turn limiting the amount 
of bias introduced. 
3.2.2 Predictors 
Predictors for each of the three diseases to be predicted were identified through review of the 
relevant literature.  
Table 3: Disease Predictors 
Diabetes Hypertension Osteoarthritis 
Hypertension (36,63) 
Older age (36,63) 
Lipid disorders (36) 
Obesity (35,36,63,70) 
Waist circumference 
Smoking (36,63) 
Stress (36) 
Male sex (36) 
Polycystic ovarian 
syndrome (PCOS) (64) 
Schizophrenia (65,66) 
Depression (67) 
Bipolar disorder (66,68) 
Low physical activity (70) 
Family history of type 2 
diabetes (36) 
Air pollution (69) 
Low socioeconomic status 
(70) 
Older age (93) 
Diabetes (93,94) 
Obesity (93,94) 
Smoking (93) 
Stress (97) 
Kidney disease (95) 
Tricyclic antidepressant 
(TCA) use (98) 
High salt intake (93,99) 
Sleep apnea (96) 
Osteoporosis (39) 
Previous leg injury 
(38,40,117,119) 
Leg length inequality (115) 
Older age (39,40,116–118) 
Obesity (38–40,116–119) 
Female sex (39,40,116,117) 
Family history of 
osteoarthritis (116) 
Physically intensive 
occupations (116) 
 
 
Table 4: Shared Risk Factors 
 Diabetes Hypertension Osteoarthritis 
Older age X X X 
Obesity X X X 
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Smoking X X  
Stress X X  
Hypertension X   
Lipid disorders X   
Waist circumference X   
Male sex X   
Female sex   X 
PCOS X   
Schizophrenia X   
Depression X   
Bipolar disorder X   
Low physical 
activity X   
Air pollution X   
Low socioeconomic 
status X   
Diabetes  X  
Kidney disease  X  
Tricyclic 
antidepressant use  X  
High salt intake  X  
Sleep apnea  X  
Osteoporosis   X 
Previous leg injury   X 
Leg length 
inequality   X 
Family history of 
type 2 diabetes X   
Family history of 
osteoarthritis   X 
Physically intensive 
occupations   X 
For each predictor, an algorithm for the identification of each risk factor was developed. Where a 
CPCSSN validated case-detecting algorithm was available, this was used; otherwise the 
following process was used to identify information that described the predictor. First, the 
CPCSSN data dictionary (181) was examined to determine if any fields contained information 
describing the predictor exactly (for example, BMI was found in the exam table). Next, other 
methods of detecting the predictor were identified, then investigated for their presence within 
CPCSSN. These included diagnostic terms and ICD-9 codes; medications used specifically to 
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treat a given condition; and laboratory test results indicative of a given condition (for example, 
an LDL measurement between 3.37 and 9 mmol/L was indicative of a lipid disorder). All 
diagnostic codes in the CPCSSN database are stored as ICD-9 codes, thus only ICD-9 codes 
were used. Multiple inclusion terms were used to capture all terminologies used to describe the 
condition; additionally, exclusion terms were used to exclude those that did not describe the 
condition. All methods of identifying predictors were reviewed by a PCP who was a member of 
the study team to ensure accuracy (for example, the PCP ensured that all medications used to 
identify predictors are medications only prescribed for the predictor condition). Subsequently, 
predictor information was compiled into predictor case-detecting algorithms that would be used 
to identify cases of predictor presence. Case definitions for each risk factor can be found in 
Appendix B. 
An estimate of income was obtained using the Forward Sortation Area (FSA) available for most 
patients. Full postal codes are unavailable in the CPCSSN data for privacy reasons. Each 
patient’s FSA, where available, was matched to average personal income according to the 
National Household Survey (NHS) conducted in 2011 (194). Similarly, rurality was based on 
postal code. The second digit of a postal code is used to denote whether the area is urban or rural. 
A zero indicates that the area is rural, while all other digits indicate urban areas (195). Where the 
second digit of the FSA was zero, the patient was considered to live in a rural area. 
Interaction terms were considered; however, no interactions were suggested in the existing 
literature (196).  
As suggested in TRIPOD (150), all continuous risk factors were kept in their original form, 
rather than binning them into categories, in order to maximize the amount of information 
available for each covariate.  
3.3 Participants 
Participants were drawn from the CPCSSN primary care database. The PPM that was developed 
for this thesis is intended to be deployed in primary care in Canada to address risk of multiple 
diseases in adults. All patients aged 18 or older were included in the cohort, irrespective of prior 
morbidities. Patients who have previously been diagnosed with all three diseases (diabetes, 
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hypertension, and osteoarthritis) were excluded, as these patients were not at risk of developing 
any of these diseases. All eligible patients were considered for analysis. 
3.4 Sample Size Considerations 
The retrospective cohort made use of all available patient data; no sub-sampling of the CPCSSN 
database was done. The cohort was split into two partitions: one for model development and one 
for validation.  
Often the minimum required size for each partition to be confident in risk estimations is 
determined by an anecdotal heuristic stating that for each predictor, there should be at least 10 
events (in this case, 10 patients who develop the disease(s) of interest). This method has been 
commonly criticized for the lack of evidence supporting its use (197). However, no method has 
been agreed upon to determine the sufficient number of events per variable; thus, in order to 
maximize the number of events per variable, predictors were only selected for use where external 
evidence of an association existed. 
3.5 Cohort Construction 
From the time-stamped records, a retrospective cohort was constructed. To begin, all patients 
listed in the patient table were considered. Patient “recruitment” began 1 January 2009 and ended 
31 December 2010 (a period of two years); patients who had any EMR entry (billing occurrence, 
encounter recording, encounter diagnosis, exam recording, or health condition recording) in the 
recruitment time period were included. For each patient, the date of the first record within the 
recruitment time period was considered the patient’s unique start-date. At this point, predictors 
(including diabetes, hypertension, and osteoarthritis, as one may predict for another) were 
assessed using the disease and predictor case definitions (Appendix B). Patients who had been 
previously diagnosed with all 3 diseases were excluded, as these patients were not at risk of 
developing the diseases. Additionally, patients younger than 18 years of age were excluded. Any 
diagnoses of disease within the subsequent 5-year period were noted.  
The cohort was randomly divided into development and validation datasets at approximately a 
2:1 ratio: the development set for model selection and parameter estimation and the validation set 
for assessing discrimination and calibration of the resulting model. 
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3.6 Missing Data 
As data in an EMR are collected for clinical purposes, not specifically for research use, data are 
often missing from the EMR because they are not relevant for patient care, despite being highly 
relevant for research. Data can be missing in a variety of ways. Data can be missing completely 
at random (MCAR), where the reason that the data are missing is independent of all other 
variables, observed or unobserved (198). For example, data that are artificially sub-sampled at 
random would be MCAR. Where data are MCAR and must be omitted from analysis, analyses 
have less power but remain unbiased. Data are missing at random (MAR) when their 
missingness can be explained by the value of observed variables (198).  For example, a lab test 
result for cholesterol may be missing because a patient is observed to be young and have normal 
BMI. Where data are MAR, techniques can be used to impute missing data using strategies that 
minimize the amount of bias that is introduced. Data are missing not at random (MNAR) where 
their missingness is dependent upon some unobserved variable, including the missing variable 
itself (198). For example, a blood pressure measurement may not be recorded because it is within 
normal ranges. Analyses based on MNAR missing data will produce biased results (198). Most 
methods to address missing data assume data to be MAR; the validity of this assumption impacts 
the amount of bias introduced into analyses.  
Imputation is the process of replacing missing values with plausible values. Depending on how 
the data are missing, different imputation methods can be used. Common examples of imputation 
include last observation carried forward (199), in which the missing value is replaced with the 
last value that was observed; mean substitution (199), in which the missing value is replaced 
with the mean of the characteristic’s observed values; and regression (199), in which other 
observed characteristics of the individual are used to estimate a value for the missing value. 
These methods are single imputation methods, which do not account for the uncertainty in the 
imputed values (200). In contrast, multiple imputation can be used to replace missing values 
while accounting for the uncertainty in the imputations by creating multiple estimates for the 
missing value (200). In multiple imputation, several values are estimated for the missing value, 
creating multiple imputed datasets. There are several methods of multiple imputation. For this 
work, multiple imputation by chained equations (MICE) was used. MICE follows these steps, as 
described by Azul et al. (201): 1) A simple imputation, such as mean substitution, is used to 
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complete all missing values. These imputed values should be thought of as placeholders. 2) One 
variable with missing data is selected as the variable of interest, var. The values for var that were 
originally missing are set back to missing. 3) These now missing values are imputed using 
regression based on all variables, including those containing placeholders. Var can be thought of 
as the dependent variable, for which the other variables serve as independent variables. 
Subsequent imputations using var as an independent variable for other variables will use these 
imputed values. 4) Steps 2 & 3 are repeated for each variable with missing data. Imputed values 
from previous cycles are used instead of the placeholders. 5) Steps 2 through 4 will be repeated a 
given number of times, updating the imputations each time, resulting in multiple imputed 
datasets. 
Multiple imputation was used for this study, which produced multiple completed datasets. While 
a single point estimate will be presented for each statistic, in actuality, several were computed 
(one for each imputed dataset); these results were then combined using Rubin’s rules (200) to 
create a single statistic whose variance has been adjusted to account for the uncertainty of 
deriving an estimate from multiple datasets. 
3.7 Statistical Analysis 
To facilitate the construction of a PPM for diabetes, hypertension, and osteoarthritis, an analysis 
of the dependence between these diseases was performed. As described above, copulas were 
selected to model the dependence between diseases because of their ability to account for more 
than two diseases, adjust for both continuous and discrete variables, and ultimately be used to 
construct a PPM. The steps in dependence modelling using copulas are: 1) univariate (marginal) 
models are constructed for each outcome and 2) copulas are used to describe the dependence 
between outcomes (202,203). 
3.7.1 Univariate Multivariable Logistic Regression 
To address Objective 1, univariate multivariable logistic regression models of the development 
of each disease were constructed. Three univariate models were produced, one for each disease 
to estimate its marginal distribution. For each disease, a subgroup of the development cohort who 
were free of the disease being predicted at baseline were included in the estimation of the 
univariate model. For example, a subgroup of patients who did not have diabetes at baseline 
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were used to construct the diabetes univariate model. The ?̂?𝑖 coefficient estimates of each model 
are presented along with 95% confidence intervals for the 𝛽𝑖. Internal validation assessing 
discrimination and calibration was performed. Discrimination refers to the ability of the model to 
assign a higher estimated risk to a person who ultimately experiences the outcome compared to a 
person who does not.  For discrimination, models were assessed by calculating the area under the 
receiver operator characteristic curve (AUC). Calibration examines how well the model fits the 
data. For calibration, models were assessed by constructing calibration plots. As the dataset was 
extremely large, methods such as cross-validation (161) or bootstrapping (162) were not 
necessary; instead, discrimination and calibration were assessed using the validation set. 
3.7.2 Analysis of Dependence 
To address Objective 2, an analysis of the dependence between each outcome was conducted 
both with and without adjustment for risk factors, in a purely descriptive (non-predictive) 
framework and then in a predictive framework. Each analysis of dependence was conducted in a 
pairwise fashion; specifically, the dependence between diabetes and hypertension, diabetes and 
osteoarthritis, and hypertension and osteoarthritis was estimated. To be included in a pairwise 
analysis, a patient had to be free of both diseases under investigation at baseline. For example, 
only patients free of both diabetes and hypertension at baseline were included in any analysis of 
the dependence between diabetes and hypertension. 
To begin, the pairwise unadjusted correlation between each outcome was measured using the ϕ 
coefficient (also known as the mean square contingency coefficient). The ϕ coefficient is a 
measure of association between two binary variables, similar to the Pearson correlation 
coefficient for continuous variables (204). In fact, estimating a Pearson correlation coefficient for 
two binary variables gives the ϕ coefficient (204). Pairwise ϕ coefficients were calculated along 
with the corresponding test statistic and 95% confidence interval.  
Partial correlation examines the correlation that exists between variables after adjusting for the 
effect of other variables; again, this is measured using the ϕ coefficient. Partial correlations were 
determined for each outcome pair, adjusted for the combined risk factors for each outcome using 
the function pcor from the ppcor R package (205).  
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Subsequently, copulas were used to describe the dependence between outcomes. The choice of 
copula was determined by the structure of the dependence. For this study, the Frank copula (170) 
was selected for used based on its ability to capture weak dependence. When modelling the 
dependence between binary variables, the copula is defined by both θ and the marginal 
distributions (202). As such, the two-stage estimation procedure based on the composite 
likelihood suggested by Zhao and Joe (203) was used for the estimation of θ. First, the marginal 
models were determined using the maximum likelihood estimation procedure. This step yielded 
β estimates that were used in the second step. From these univariate models, the probabilities for 
the independent occurrence of each outcome were estimated, by: 
𝜋𝑗(𝐱) =  
exp (𝐱T𝜷𝒋)
1 + exp (𝐱T𝜷𝒋)
 
where 𝜷𝒋 is a vector containing the β estimates for each outcome j and x is a matrix of covariate 
data. Second, estimates of θ were obtained, again using the maximum likelihood estimation 
procedure. This process made use of the bivariate conditional distributions of each outcome pair. 
From these, the likelihood function was constructed. By setting the derivative of the log 
likelihood function (known as the score function, 𝑠𝜃) equal to zero, θ was estimated.  
𝑠𝜃(𝜃, 𝛽𝑘, 𝛽𝑙) =  ∑ ?̇?𝜃(?̅?𝑖𝑘, ?̅?𝑖𝑙) (
(1 − 𝑌𝑖𝑘)(1 − 𝑌𝑖𝑙)
𝐶𝜃(?̅?𝑖𝑘, ?̅?𝑖𝑙)
−
(1 − 𝑌𝑖𝑘)𝑌𝑖𝑙
?̅?𝑖𝑘 − 𝐶𝜃(?̅?𝑖𝑘, ?̅?𝑖𝑙)
−
𝑌𝑖𝑘(1 − 𝑌𝑖𝑙)
?̅?𝑖𝑙 − 𝐶𝜃(?̅?𝑖𝑘, ?̅?𝑖𝑙)
𝑛
𝑖=1
+
𝑌𝑖𝑘𝑌𝑖𝑙
1 − ?̅?𝑖𝑘 − ?̅?𝑖𝑙 + 𝐶𝜃(?̅?𝑖𝑘, ?̅?𝑖𝑙)
) 
?̇?𝜃(𝑢, 𝑣) =
𝑒𝜃𝜃((𝑢 − 1)(−𝑒𝜃𝑣)−𝑒𝜃(𝑢+𝑣) + 𝑢𝑒𝜃𝑣+𝜃 − (𝑣 − 1)𝑒𝜃𝑢 + 𝑣𝑒𝜃𝑢+𝜃 − 𝑒𝜃(𝑢 + 𝑣) + 𝑢 + 𝑣 − 1)
(𝑒𝜃 − 1)(−𝑒𝜃(𝑢+𝑣) + 𝑒𝜃𝑢+𝜃 + 𝑒𝜃𝑣+𝜃 − 𝑒𝜃)
+ ln (
(𝑒−𝜃𝑢 − 1)(𝑒−𝜃𝑣 − 1)
𝑒−𝜃 − 1
+ 1)
𝜃2
 
?̅?𝑖𝑘 =  1 − 𝜋𝑖𝑘 
?̅?𝑖𝑙 =  1 − 𝜋𝑖𝑙 
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where 𝐶𝜃 is the copula function; ?̇?𝜃 is the derivative of the copula function; 𝜋𝑖𝑘 and 𝜋𝑖𝑙 are 
estimated probabilities of disease k and l for patient i based on their univariate models, 
respectively; and 𝑌𝑖𝑘 and 𝑌𝑖𝑙 are the observed disease outcomes for patient i. 
A dependence structure using copulas is completely specified by its univariate multivariable 
models and copula, which is specified by its θ estimate. Estimates of the parameter θ were 
obtained for each disease pair. Bootstrapping was used to construct confidence intervals for the θ 
estimates; the percentile method was used (206), in which the sample means at the 2.5 and 97.5 
percentiles were used to approximate the confidence interval based on one thousand 
bootstrapped replicates. Additionally, the following hypothesis test based on the score test was 
used to test the null hypothesis that the observed outcome frequencies are no different than what 
would be expected under independence (202). The null hypothesis was rejected if 𝓏𝑜𝑏𝑠 is larger 
in absolute value than a critical value derived from the standard Normal distribution, denoted 
N(0,1).  
𝓏𝑜𝑏𝑠 = ∑
?̇?𝜃0(?̂̅?𝑖𝑘, ?̂̅?𝑖𝑙)(𝑌𝑖𝑘 − ?̂?𝑖𝑘)(𝑌𝑖𝑙 − ?̂?𝑖𝑙)
?̂?𝑖𝑘?̂?𝑖𝑙 ?̂̅?𝑖𝑘 ?̂̅?𝑖𝑙
/√∑
?̇?𝜃0
2 (?̂̅?𝑖𝑘 ?̂̅?𝑖𝑙)
?̂?𝑖𝑘?̂?𝑖𝑙 ?̂̅?𝑖𝑘 ?̂̅?𝑖𝑙
𝑛
𝑖=1
𝑛
𝑖=1
 
Based on these copula models, trivariate probabilities that account for the dependence between 
outcomes can be estimated; that is, the probabilities of each combination of diseases will be 
estimated. Each trivariate probability can be described as a probability mass function. 
𝑝(𝑥1, 𝑥2, 𝑥3) = 𝑝(𝑋1 =  𝑥1, 𝑋2 =  𝑥2, 𝑋3 =  𝑥3) 
Bivariate probability mass functions can be used to describe the marginal distributions of the 
trivariate probability mass functions.  
𝑝(𝑥1, 𝑥2) = ∑ 𝑝(𝑥1, 𝑥2, 𝑥3)
𝑥3∈ {0,1}
 
Similar expressions are true for 𝑝(𝑥1, 𝑥3) and 𝑝(𝑥2, 𝑥3). Based on ?̂?(𝑥1, 𝑥2), ?̂?(𝑥1, 𝑥3), and 
?̂?(𝑥2, 𝑥3) as estimated by the copula model, trivariate probability mass functions (?̂?(𝑥1, 𝑥2, 𝑥3)) 
can be found that satisfy the bivariate marginal distributions. In fact, there may be many 
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combinations of trivariate probability mass functions that satisfy this relationship; the 
combination with the highest entropy (207) (highest uncertainty) was chosen, as this gives the 
most conservative estimate. From this analysis, the trivariate probabilities can be estimated. For 
example, the risk of developing diabetes, hypertension, and osteoarthritis all within a 5-year 
window can be estimated. 
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Chapter 4  
4 Results 
The following chapter first provides descriptive statistics about the study cohort. This is followed 
by the analysis of dependence using copulas. First, the univariate multivariable logistic 
regression models are presented. Next, both unadjusted and adjusted dependence analyses, 
including the copulas, are presented. Finally, the copulas are used to estimate the risk of multiple 
diseases for two simulated patients. 
4.1 Descriptive Statistics 
A cohort of 425228 adult patients who did not have comorbid diabetes, hypertension, and 
osteoarthritis who had received care between 1 January 2009 and 31 December 2010 were 
followed for 5 years. Figure 4 details the flow of patients into the cohort. The final cohort was 
split into a development set of 265228 patients (62%) and a validation set of 160000 patients 
(38%). Most patients began the period of study without morbidities (70%) (the following 
diseases were considered when assessing morbidities: asthma, arthritis, COPD, diabetes, 
cardiovascular disease, mental disorder (mood disorder and/or anxiety), Alzheimer's disease and 
related dementias, cancer, and stroke). The most common condition was having a lipid disorder 
(17.9%). The majority of patients were female (58.1%), which is typical of a primary care 
population (189–191). The average age of patients was 47.1 years old (standard deviation: 18.0 
years). Most patients were overweight or obese (64.1%). After the 5-year period, hypertension 
was the most commonly acquired disease, with an incidence proportion of 9.4% and an incidence 
rate of 0.0818 events/person-year, followed by diabetes with an incidence proportion of 4.4% 
and an incidence rate of 0.0413 events/person-year. Osteoarthritis was developed by the least 
number of patients, with an incidence proportion of 3.0% and an incidence rate of 0.0248 
events/person-year. No significant differences between the development and validation sets were 
observed. For a detailed description of all patient characteristics, see Table 6; note that each 
percentage denotes the percent of patients with the risk factor among those who had complete 
information for that risk factor. Each risk factor has been compared to its national prevalence 
from approximately 2010. 
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Figure 3: Cohort Construction 
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Table 5: Incidence of Diabetes, Hypertension, and Osteoarthritis 
 Entire Cohort (n = 
425228) 
Development Set (n 
= 265228) 
Validation Set (n = 
160000) 
Diabetes 
Incidence 
Proportion, n (%) 
18769 
(4.4%) 
11677 
(4.4%) 
7092 
(4.4%) 
Incidence rate, 
events/person-year 
(95% CI) 
0.0415 
(0.0409 to 0.0421) 
0.0413 
(0.0406 to 0.0421) 
0.0418 
(0.0408 to 0.0428) 
Hypertension 
Incidence 
Proportion, n (%) 
39882 
(9.4%) 
24828 
(9.4%) 
15054 
(9.4%) 
Incidence rate, 
events/person-year 
(95% CI) 
0.0818 
(0.0810 to 0.0826) 
0.0816 
(0.0806 to 0.0827) 
0.0820 
(0.0807 to 0.0833) 
Osteoarthritis 
Incidence 
Proportion, n (%) 
12803 
(3.0%) 
7980 
(3.0%) 
4823 
(3.0%) 
Incidence rate, 
events/person-year 
(95% CI) 
0.0248 
(0.0243 to 0.0252) 
0.0248 
(0.0242 to 0.0253) 
0.0248 
(0.0241 to 0.0255) 
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Table 6: Descriptive Statistics 
 Entire Cohort (n = 425228) Development Set (n = 265228) Validation Set (n = 160000)  
 n cases % n cases % n cases % 
National 
Prevalence 
Osteoarthritis 41853 9.8% 26013 9.8% 15840 9.9% 13.0%𝑎 
Diabetes 28979 6.8% 18140 6.8% 10839 6.8% 8.7%𝑏 
Hypertension 66030 15.5% 41185 15.5% 24845 15.5% 17.6%𝑐 
Depression 61977 14.6% 38629 14.6% 23348 14.6% 11.3%𝑑 
Smoking 17844 63.9% 11037 63.8% 6807 64.2% 13.7%𝑒 
Female Sex 246866 58.1% 153664 57.9% 93202 58.3% 50.4%𝑓 
Alcohol 6467 1.5% 4038 1.5% 2429 1.5% 2.4%𝑔 
Stress 12636 3.0% 7907 3.0% 4729 3.0% 22.9%ℎ 
Epilepsy 2979 0.7% 1842 0.7% 1137 0.7% 0.4%𝑖 
Schizophrenia 6379 1.5% 3955 1.5% 2424 1.5% 1.0%𝑗 
Anxiety 30326 7.1% 18894 7.1% 11432 7.1% > 12%𝑘 
Cancer 17653 4.2% 11139 4.2% 6514 4.1% 7.1%𝑙 
CVD 23502 5.5% 14730 5.6% 8772 5.5% 5.4%ℎ 
COPD 7265 1.7% 4515 1.7% 2750 1.7% 8.7%𝑚 
Rheumatoid Arthritis 3263 0.8% 2039 0.8% 1224 0.8% 0.9%𝑛 
Lipid Disorder 76253 17.9% 47619 18.0% 28634 17.9% 17.3%𝑜 
PCOS 1154 0.5% 706 0.5% 448 0.5% 6.5%𝑝 
CKD 14767 3.5% 9283 3.5% 5484 3.4% 3.1%𝑞 
TCA 13035 3.1% 8114 3.1% 4921 3.1%  
Osteoporosis 14384 3.4% 8971 3.4% 5413 3.4% 10.0%𝑟 (40+) 
Leg Injury 12411 2.9% 7808 2.9% 4603 2.9%  
Family History of 
Osteoarthritis 282 0.1% 168 0.1% 114 0.1%  
Family History of DM 4578 1.1% 2851 1.1% 1727 1.1%  
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 Entire Cohort (n = 425228) Development Set (n = 265228) Validation Set (n = 160000)  
 n cases % n cases % n cases % 
National 
Prevalence 
Family History of 
Hypertension 2904 0.7% 1817 0.7% 1087 0.7%  
Lives in a rural location 88898 20.9% 55527 20.9% 33371 20.9% 19.0%𝑠 
Morbidity 
     -1 disease* 127781 30.0% 79671 30.0% 48110 30.1% 38.4%𝑡  
Multimorbidity 
     -2 disease* 37679 8.9% 23565 8.9% 14114 8.8% 14.5%𝑢 
     -3 disease* 10063 2.4% 6286 2.4% 3777 2.4% 4.9%𝑢 
Age 
     -18 to 24 58947 13.9% 36962 13.9% 21985 13.7% 12.0%𝑣 
     -25 to 44 143660 33.8% 89608 33.8% 54052 33.8% 34.5%𝑣 
     -45 to 64 152924 36.0% 95161 35.9% 57763 36.1% 35.8%𝑣 
     -65 and older 69438 16.3% 43330 16.3% 26108 16.3% 17.7%𝑣 
BMI 
     -Underweight (< 18.5 
kg/m2) 2694 1.9% 1680 1.9% 1014 1.9%  
     -Normal (18.5 to 24.9 
kg/m2) 48920 34.0% 30541 34.1% 18379 33.9% 32%𝑤  
     -Overweight (25 to 
29.9 kg/m2) 49380 34.3% 30736 34.3% 18644 34.4% 40%𝑤  
     -Obese (> 30 kg/m2) 42834 29.8% 26639 29.7% 16195 29.9% 27%𝑤  
Personal Income 
     -Less than $30000 2243 0.6% 1401 0.6% 842 0.6%  
     -$30000 to $49999 297791 73.9% 185981 74.0% 111810 73.8%  
     -$50000 to $74999 102784 25.5% 64016 25.5% 38768 25.6%  
     -Greater than $75000 7 0.0% 6 0.0% ** 0.0%  
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Canadian 𝑎 Chronic Disease Surveillance System (CCDSS) 2013/14(28) 
Canadian 𝑏 Chronic Disease Surveillance System (CCDSS) 2008(208) 
Canadian 𝑐 Community Health Survey (CCHS) 2011 (209) 
Canadian 𝑑 Community Health Survey (CCHS) 2012 (210) 
Canadian 𝑒 Tobacco Use Monitoring Survey (CTUMS) 2012 (208) 
Statistics Canada 𝑓 (211) 
National Population Health Survey 𝑔 (NPHS) 2006 (212) 
Canadian ℎ Community Health Survey (CCHS) 2009/10 (208) 
Canadian 𝑖 Community Health Survey (CCHS) 2010/11 (213) 
Public Health Agency of Canada 𝑗 (214) 
Offord et al 𝑘 (215) 
Canadian 𝑙 Community Health Survey (CCHS) 2015 (29) 
Canadian 𝑚 Chronic Disease Surveillance System (CCDSS) 2008 (208) 
Ontario Rheumatoid Arthritis administrative Database 𝑛 (ORAD) (216) 
Canadian 𝑜 Health Measures Survey (CHMS) 2009/10 (208) 
Lujan et al.𝑝  (217) 
Canadian 𝑞 Health Measures Survey (CHMS) 2007/08 (218) 
2009 Canadian𝑟  Community Health Survey – Osteoporosis Rapid Response (219) 
Statistics Canada 𝑠  (220) 
Canadian 𝑡 Community Health Survey (CCHS) 2014 (29) 
Canadian 𝑢 Community Health Survey 2011/12 (208) 
Canadian 𝑣 Census 2012 (221) 
Canadian 𝑤 Health Measures Survey (CHMS) 2009/10 (222) 
*Morbidity and multimorbidity considered the following diseases: asthma, arthritis, COPD, diabetes, cardiovascular disease, mental 
disorder (mood disorder and/or anxiety), Alzheimer's disease and related dementias, cancer, stroke. 
**Cell counts of 5 or less have been suppressed. 
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4.2 Missing Data and Multiple Imputation 
Table 7 displays the amount of missing data in fields where data were missing, such as age or 
BMI. All other variables were assessed under the assumption that the absence of an indication of 
risk factor presence signified that the risk factor was not present in the individual. However, in 
some cases, when compared to national averages, this assumption seemed unreasonable. For 
example, a diagnosis of polycystic ovarian syndrome (PCOS) was found in only 0.5% of women, 
whereas the national average of PCOS among women was 6.5%. As this seemed implausible, 
PCOS was not considered in any analyses. The same approach was used in removing alcohol 
use. Information regarding family history of the diseases of interest was not readily available for 
most patients as several networks did not collect this information; family history was removed 
accordingly. 
Table 7: Variables with Missing Data 
 Entire Cohort (n = 
425228) 
Development Set (n = 
265228) 
Validation Set (n = 
160000) 
 n missing % n missing % n missing % 
Smoking 397319 93% 247918 93% 149401 93% 
Sex 69 0.02% 44 0.02% 25 0.02% 
BMI 281400 66% 175632 66% 105768 66% 
Age 259 0.061% 167 0.063% 92 0.058% 
Income 22403 5.27% 13824 5.21% 8579 5.36% 
Multiple imputation was used to account for missing data in sex, BMI, age, and income. Five 
iterations were used, creating five imputed datasets. Smoking was not considered in analyses 
because there was not sufficient information available to reliably perform imputation. 
Risk factors deemed sufficiently well-recorded in the database and thus included in the models 
were:  
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Table 8: Risk Factors Available Within CPCSSN Database 
Osteoarthritis Diabetes Hypertension 
Osteoporosis 
Previous leg injury 
Older age 
Obesity 
Female sex 
Hypertension 
Older age 
Lipid disorders 
Obesity 
Male sex 
Schizophrenia 
Depression   
Low socioeconomic status 
Older age 
Diabetes 
Obesity 
Kidney disease 
Tricyclic antidepressant 
(TCA) use 
4.3 Univariate Results 
As described in Objective 1, the following results describe the univariate multivariable logistic 
regression models that were constructed for diabetes, hypertension, and osteoarthritis. First, the 
estimated β coefficients and odds ratios (with 95% confidence intervals) are presented followed 
by model validation measures such as the ROC curve, AUC, and calibration plot for each model. 
Note that direct comparisons of the magnitude of the estimated β coefficients to determine their 
relative impact on disease risk would be inappropriate as these parameters were constructed for 
the purpose of prediction, rather than causal inference. However, the significance of each 
estimate can be considered. Of greatest importance are the model validation measures, as these 
provide insight into model performance. 
Table 9: Diabetes Univariate Results 
 Reference 
Category/Units 
β estimate 95% CI Odds Ratio 95% CI 
Hypertension No Reference Reference 
Yes 0.30 0.26 to 0.35 1.35 1.30 to 1.42 
Age (Years) 0.04 0.03 to 0.04 1.04 1.03 to 1.04 
Lipid 
disorders 
No Reference Reference 
Yes 1.69 1.64 to 1.73 5.42 5.16 to 5.87 
BMI (kg/m2) 0.07 0.07 to 0.08 1.07 1.07 to 1.08 
Sex Male Reference Reference 
Female -0.30 -0.34 to -0.26 0.74 0.71 to 0.77 
Schizophrenia No Reference Reference 
Yes 0.63 0.51 to 0.75 1.88 1.67 to 2.12 
Depression No Reference Reference 
Yes 0.14 0.08 to 0.20 1.15 1.08 to 1.22 
Income ($10000) -0.89 -1.15 to -0.64 0.41 0.32 to 0.53 
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Figure 4: ROC Curve for Diabetes 
 
Figure 5: Calibration Plot for Diabetes 
AUC = 0.85 
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All estimated β coefficients for the diabetes model were found to be significant, as expected 
given the large sample size. The model discriminated very well, as indicated by its ROC curve 
and AUC (0.8523; 0.8476 to 0.8570). It slightly overestimated risk in lower risk patients, while it 
estimated higher risk patients quite well (only a very slight underestimation), as depicted in its 
calibration plot. 
Table 10: Hypertension Univariate Results 
 Reference β estimate 95% CI Odds Ratio 95% CI 
Diabetes No Reference Reference 
Yes 0.18 0.12 to 0.23 1.19 1.13to 1.26 
Age (Years) 0.07 0.06 to 0.07 1.07 1.06 to 1.07 
BMI (kg/m2) 0.06 0.06 to 0.07 1.06 1.06 to 1.07 
Chronic 
Kidney 
Disease 
No Reference Reference 
Yes 0.80 0.74 to 0.85 2.22 2.09 to 2.35 
Tricyclic 
Antidepressant 
Use 
No Reference Reference 
Yes 0.55 0.49 to 0.62 1.74 1.63 to 1.86 
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Figure 6: ROC Curve for Hypertension 
 
Figure 7: Calibration Plot for Hypertension 
AUC = 0.84 
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Again, all estimated β coefficients from the hypertension univariate model were found to be 
significant. The model discrimination was high, as indicated by its ROC curve and AUC 
(0.8391; 0.8353 to 0.8429). It slightly underestimated risk in lower risk patients, while it 
overestimated risk in moderate and higher risk patients, as depicted in its calibration plot. 
Table 11: Osteoarthritis Univariate Results 
 Reference β estimate 95% CI Odds Ratio 95% CI 
Age (Years) 0.06 0.05 to 0.06 1.06 1.05 to 1.06 
Sex Male Reference Reference 
Female 0.22 0.17 to 0.27 1.25 1.19 to 1.31 
BMI (kg/m2) 0.04 0.03 to 0.04 1.04 1.04 to 1.05 
Previous Leg 
Injury 
No Reference Reference 
Yes 1.60 1.52 to 1.68 4.94 4.57 to 5.35 
Osteoporosis No Reference Reference 
Yes 0.90 0.83 to 0.98 2.47 2.29 to 2.66 
 
 
Figure 8: ROC Curve for Osteoarthritis 
AUC = 0.83 
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Figure 9: Calibration Plot for Osteoarthritis 
Similar to the previous models, the estimated β coefficients for the osteoarthritis model were 
found to be significant. Model discrimination was high, as indicated by its ROC curve and AUC 
(0.8394; 0.8342 to 0.8446). It slightly overestimated risk in most patients, with the risk of those 
at moderate risk overestimated the most and slight underestimation at both extremes. 
4.4 Dependence Analysis 
To measure the unadjusted correlation between outcomes, the ϕ coefficient was computed for 
each outcome pair using the cor.test function in R. All pairs showed positive correlation. As 
shown in Table 12, diabetes and hypertension were the most correlated outcomes, followed 
closely by hypertension and osteoarthritis. Diabetes and osteoarthritis were the least correlated. 
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Table 12: ϕ Coefficients 
 Diabetes Hypertension Osteoarthritis 
Diabetes 1   
Hypertension 
0.2420 
(0.2380 to 0.2460, 
p < 0.0001) 
1  
Osteoarthritis 
0.0975 
(0.0934 to 0.1016, 
p < 0.0001) 
0.2086 
(0.2045 to 0.2127, 
p < 0.0001) 
1 
Partial correlation was also computed for each outcome pair using the pcor function, which 
adjusted for the effects of all risk factors for both outcomes. For example, the partial correlation 
between diabetes and hypertension was adjusted for all risk factors associated with diabetes 
and/or hypertension. Again, all pairs were positively correlated, though the magnitudes of 
correlation were reduced. As seen in Table 12, partial correlation was highest between diabetes 
and hypertension; then hypertension and osteoarthritis; and diabetes and osteoarthritis. 
Table 13: Partial Correlation 
 
Diabetes Hypertension Osteoarthritis 
Diabetes 1   
Hypertension 
0.1323 
(0.1281 to 0.1366, 
p < 0.0001) 
1  
Osteoarthritis 
0.0377 
(0.0336 to 0.0419, 
p < 0.0001) 
0.1227 
(0.1183 to 0.1270, 
p < 0.0001) 
1 
For each outcome pair, a copula was constructed to describe the non-linear dependence between 
outcomes while adjusting for covariates using the univariate multivariable logistic regression 
models. The Frank copula (170)  was selected for use, given its ability to model weak 
dependence well. The Frank copula can be seen below: 
𝐶𝜃(𝑢, 𝑣) =  −
1
𝜃
ln (1 +
(𝑒−𝜃𝑢 − 1)(𝑒−𝜃𝑣 − 1)
𝑒−𝜃 − 1
) 
Following the construction of univariate models for each outcome, estimates of the copula 
parameter θ were obtained for each disease pair. Results from the estimation of θ for each 
outcome pair are displayed in Table 13. A positive θ estimate represents a positive dependence 
  
59 
(i.e., diseases tend to either both occur or not occur), while a negative θ estimate represents a 
negative dependence (i.e., patients tend to develop one disease or the other but not both). The 
strength of the dependence can be inferred from the magnitude of the θ estimate. 
Table 14: θ Estimates 
 
Diabetes Hypertension Osteoarthritis 
Diabetes    
Hypertension 1.6766 
(1.5657 to 1.7876, 
p < 0.0001) 
  
Osteoarthritis 0.6830 
(0.5256 to 0.8405 
p < 0.0001) 
1.9490 
(1.8224 to 2.0755, 
p < 0.0001) 
 
All disease pairs exhibited a significant positive dependence after adjusting for risk factors, as 
demonstrated by their θ estimates greater than zero. 
Based on these copula models, trivariate probabilities were estimated. The following are 
simulated patients whose trivariate probabilities have been estimated. For comparison, trivariate 
probabilities under the assumption of independence have been estimated. The ratio between 
these is presented for comparison purposes. Ratios greater than one indicate a higher risk based 
on the copula than when assuming independence.  
Example patient 1:  Fifty-nine-year-old male whose BMI is 29 kg/m2, who has osteoporosis and 
an income of roughly $40000. 
Table 15: Trivariate Probabilities for Example Patient 1 
P(Diabetes, Hypertension, 
Osteoarthritis) 
Based on copula 
model 
Based on independence 
assumption Ratio 
P(0,0,0) 0.8221 0.8132 1.01 
P(0,0,1) 0.0466 0.0529 0.88 
P(0,1,0) 0.0907 0.0991 0.92 
P(1,0,0) 0.0121 0.0064 1.88 
P(0,1,1) 0.0212 0.0238 0.89 
P(1,0,1) 0.0015 0.0015 0.97 
P(1,1,0) 0.0049 0.0029 1.69 
P(1,1,1) 0.0008 0.0002 4.25 
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Example patient 2: Seventy-nine-year-old woman whose BMI is 34 kg/m2 with an income of 
roughly $35000 and free of any other risk factors. 
Table 16: Trivariate Probabilities for Example Patient 2 
P(Diabetes, Hypertension, 
Osteoarthritis) 
Based on 
copula model 
Based on independence 
assumption Ratio 
P(0,0,0) 0.6088 0.5798 1.05 
P(0,0,1) 0.0481 0.0665 0.72 
P(0,1,0) 0.2362 0.2633 0.90 
P(1,0,0) 0.0466 0.0302 1.54 
P(0,1,1) 0.0282 0.0371 0.76 
P(1,0,1) 0.0026 0.0043 0.61 
P(1,1,0) 0.0239 0.0169 1.42 
P(1,1,1) 0.0055 0.0019 2.84 
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Chapter 5  
5 Discussion 
This chapter describes the key findings from the development of a PPM for multiple diseases, 
with further discussion and elaboration. The strengths, limitations, and implications of this work 
are discussed as well. 
5.1 Overview of Results 
Univariate models were constructed for diabetes, hypertension, and osteoarthritis that can be 
used to estimate a patient’s risk of future disease development. Each model was comprised of a 
set of β estimates that describe the contribution of each risk factor. All models had good 
predictive ability, as demonstrated by their AUCs and calibration plots. Diabetes was the best 
predicted outcome, with the greatest AUC (0.85) and the best calibration plot. The hypertension 
model had the next best performance, with an AUC of 0.84 and a good calibration plot. The 
osteoarthritis model had the lowest performance of the predicted diseases, with an AUC of 0.83 
and a calibration plot that slightly underestimated risk in low-risk patients and slightly 
overestimated risk in high-risk patients.  
Following the construction of univariate models for each disease, an analysis of dependence 
between each disease was conducted. This began with an analysis of the unadjusted correlation 
measured using the ϕ coefficient. Diabetes and hypertension were the most correlated (ϕ = 
0.24), followed by hypertension and osteoarthritis (ϕ = 0.21), then diabetes and hypertension (ϕ 
= 0.10).  
Next, the correlation between diseases after adjusting for the effects of relevant risk factors 
(partial correlation) was determined. An examination of the partial correlation between each 
disease pair revealed lower correlation coefficients between outcomes. This was expected, as 
some dependence was anticipated to be explained by risk factors. Interestingly, the correlation 
between hypertension and osteoarthritis (ϕ = 0.12) became roughly the same as that of diabetes 
and hypertension (ϕ = 0.13) after adjustment. The correlation between diabetes and osteoarthritis 
  
62 
decreased almost to zero after adjustment (ϕ = 0.04), indicating that most of the observed 
association between these two diseases could be explained by their risk factors.  
Finally, construction of copula models produced θ coefficients that describe the dependence 
between outcomes that existed after adjusting for relevant risk factors. The largest θ estimate was 
observed between hypertension and osteoarthritis (θ = 1.95), indicating that the strongest 
dependence exists between this pair after adjusting for all risk factors. Diabetes and hypertension 
had the next largest θ estimate (1.68), followed by diabetes and osteoarthritis (θ = 0.68). As 
observed in the trivariate probability charts, the probability of developing multiple diseases was 
greater when based on the copula models than when assuming independence. For example, for 
example patient 1, the probability of developing all three diseases within five years was roughly 
four times greater under the copula model than when assuming independence (0.0008 vs 0.0002). 
The smallest increase was observed in the estimated probability of developing both diabetes and 
osteoarthritis, which aligns with the previous correlation analyses that found the least correlation 
between these two diseases. These findings indicate that risk estimates made under the 
assumption of independence underestimate the risk of disease co-occurrence. 
5.2 Comparisons of Univariate Models with Existing Models 
Several models have been constructed in other works to individually estimate risk of each of 
diabetes, hypertension, and osteoarthritis. In the following, the models produced by this thesis 
will be compared with these existing univariate models. 
5.2.1 Diabetes 
Several models are commonly used to estimate an individual's risk of diabetes development. 
These include the American Diabetes Association Questionnaire (ADA) (223), hosted on the 
American Diabetes Association website; the Canadian Diabetes Risk Questionnaire (CANRISK) 
(224), hosted on the government of Canada website; the Leicester Risk Assessment (LRA) (225), 
found on the Diabetes UK and the UK National Health Service websites; and Australian Type 2 
Diabetes Risk Assessment Tool (AUSDRISK) (226), found on The Australian Department of 
Health website. Compared to these tools, the model derived from the CPCSSN database includes 
many similar risk factors, with the notable addition of several diseases as risk factors, such as 
depression or schizophrenia. However, the model derived for this thesis did not include several 
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lifestyle or environmental risk factors as these were not stored in the database. The CPCSSN 
database relied on EMR data, which is limited by the nature of the data collected (only clinically 
relevant data) when compared to data collected for purpose through questionnaires or physical 
examinations. The model derived for this thesis was derived from a considerably larger cohort 
than previous models. It performed with similar, if not superior, discrimination compared to 
traditional models. A comparison of the model derived for this thesis and existing models for 
estimating diabetes risk is displayed below. 
Table 17: Comparison of Diabetes Univariate Model with Existing Models 
Name of 
tool/study 
Source 
population 
Sample size 
(development 
set) 
Data 
collection 
method 
Method of 
analysis 
Validity 
CPCSSN 
(2018) 
CPCSSN 
primary care 
records 
265228 Electronic 
medical 
records 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.85 
ADA (2009) 
(223) 
NHANES  
(National 
Health and 
Nutrition 
Examination 
Survey) 1999-
2004 
5258 Interviews, 
physical 
examinations, 
and laboratory 
tests 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.83 
eCANRISK 
(2009) (224) 
CANRISK 
study 
4366 Questionnaire Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.75 
LRA (2010) 
(225) 
Random 
sample of UK 
6390 Interviews, 
physical 
examinations, 
and laboratory 
tests 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.69 
External 
validation: 
AUC of 0.72 
AUSDRISK 
(2010) (226) 
Australian 
Diabetes, 
Obesity, and 
Lifestyle 
Study 
 6060 Interviews and 
laboratory 
tests 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.783 
External 
validation: 
AUC of 0.66 
 
Table 18: Risk Factors Included in Diabetes Risk Estimation 
Risk factor CPCSSN ADA CANRISK LRA AUSDRISK 
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Risk factor CPCSSN ADA CANRISK LRA AUSDRISK 
Age X X X X X 
Sex X X X X X 
Diabetes in 
family 
 X X X X 
High blood 
pressure 
X X X X  
Blood pressure 
medication 
use/history 
  X X  
Lipid disorder X     
Schizophrenia X     
Depression X     
Physical 
activity 
 X X  X 
Obesity (BMI) X X X X X 
Gestational 
diabetes 
 X X   
Waist 
measurement 
  X X  
Eats 
vegetables and 
fruits 
  X  X 
High blood 
glucose history 
  X  X 
Ethnic 
group/country 
of birth 
  X X X 
Level of 
education 
  X   
Income X     
Smoking     X 
5.2.2 Hypertension 
When dealing hypertension and other cardiovascular diseases, focus is often placed on predicting 
severe events such as heart attack or stroke (9) rather than hypertension. However, some 
prognostic predictive models aimed at the estimation of hypertension risk exist; these include 
models based on the Framingham Heart Study (227); Women's Health Study (228); and data 
combined from the Atherosclerosis Risk in Communities and the Cardiovascular Health Study 
(229). These models included a wide variety of risk factors. The model derived for this thesis 
included the fewest risk factors, as it was not able to include several lifestyle or environmental 
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risk factors. Despite this, it performed the best out of all models, as it had the greatest AUC. 
Compared to the other models considered, the model derived for this thesis had considerably 
more individuals in its development set. Again, a comparison of the model developed for this 
thesis and existing models used to estimate risk of hypertension are presented below. The 
following tables present a comparison of each of these models. 
Table 19: Comparison of Hypertension Univariate Model with Existing Models 
Name of 
tool/study 
Source 
population 
Sample size 
(development 
set) 
Data 
collection 
method 
Method of 
analysis 
Validity 
CPCSSN CPCSSN 
primary care 
records 
265228 Electronic 
medical 
records 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.84 
Framingham 
Heart Study 
(2008) (227) 
Population 
based 
1717 Interviews, 
physical 
examinations, 
and laboratory 
tests 
Multivariable 
Weibull 
regression 
Internal 
validation: 
AUC of 0.79 
Women's 
Health Study 
(2009) (228) 
US female 
health 
professionals 
9427 Interviews, 
physical 
examinations, 
and laboratory 
tests 
 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.71 
ARIC/CHS 
(2010) (229) 
Population 
based 
7683 Interviews, 
physical 
examinations, 
and laboratory 
tests 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.75 
ARIC: Atherosclerosis Risk in Communities Study 
CHS: Cardiovascular Health Study 
Table 20: Risk Factors Included in Hypertension Risk Estimation 
Risk factor CPCSSN Framingham 
Heart Study 
Women's 
Health Study 
ARIC-CHS 
Diabetes X   X 
Age X X X X 
Sex  X X X 
BMI X X  X 
Chronic kidney 
Disease 
X    
Tricyclic 
antidepressant 
X    
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Risk factor CPCSSN Framingham 
Heart Study 
Women's 
Health Study 
ARIC-CHS 
use 
Systolic blood 
pressure 
 X X X 
Diastolic blood 
pressure 
 X X X 
Family history 
of hypertension 
 X  X 
Ethnicity   X  
Total/HDL 
cholesterol 
  X  
Lipoprotein   X  
High-sensitivity 
C-reactive 
protein 
  X  
Total grains   X  
Current smoker    X 
Lack of exercise    X 
5.2.3 Osteoarthritis 
Several models for the estimation of osteoarthritis risk have been developed, including the Tool 
for Osteoarthritis Risk Prediction (TOARP) (230); the Nottingham knee osteoarthritis risk 
prediction models (231); and models derived from data from the Rotterdam Study-1 (232) and 
the Multicenter Osteoarthritis Study (MOST) (233). While the model derived for this thesis is 
not specific to the location of osteoarthritis (as the case definition for osteoarthritis did not 
specify the affected joint), all other models were designed to predict exclusively knee 
osteoarthritis. Similar to hypertension, osteoarthritis predictive models made use of a wide 
variety of risk factors, including radiographic measures such as the Kellgren and Lawrence 
score. The model developed for this thesis did not use any radiographic measures; in fact, it was 
the simplest model while maintaining the best discrimination according to internal validation. 
The model developed for this work was based on a considerably larger sample of patients aged 
18 and older; it did not restrict its sample to an older population at high risk of osteoarthritis in 
order to enable the estimation of risk among all adults. A thorough comparison of each of these 
models is displayed below. 
Table 21: Comparison of Osteoarthritis Univariate Model with Existing Models 
Name of Source Sample size Data Method of Validity 
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tool/study population (development 
set) 
collection 
method 
analysis 
CPCSSN CPCSSN 
primary care 
records 
265228 Electronic 
medical 
records 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.83 
Tool for 
Osteoarthritis 
Risk 
Prediction 
(TOARP) 
(2018) (230) 
Population 
based cohort 
(age 45-79) 
641 Interviews, 
physical 
examinations, 
and laboratory 
tests, 
including MRI 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.72 
Rotterdam 
Study-1 
(2014) (232) 
Population 
based cohort 
(age 55+) 
2628 Interviews, 
physical 
examinations, 
and laboratory 
tests, 
including x-
ray 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.79 
Multicenter 
Osteoarthritis 
Study 
(MOST) 
(2016) (233) 
Population 
based cohort 
(age 50-79) 
3026 Interviews, 
physical 
examinations, 
and laboratory 
tests, 
including x-
ray 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.78 
External 
validation: 
AUC of 0.76 
Nottingham 
knee 
osteoarthritis 
risk prediction 
models (2011) 
(231) 
Population 
based cohort 
(age 40+) 
424 Interviews, 
physical 
examinations, 
and laboratory 
tests, 
including x-
ray 
Multivariable 
logistic 
regression 
Internal 
validation: 
AUC of 0.70 
External 
validation: 
AUC of 0.6 
and 0.79 
 
Table 22: Risk Factors Included in Osteoarthritis Risk Estimation 
Risk factor CPCSSN TOARP Rotterdam 
Study-1 
MOST Nottingham 
Age X X X  X 
Sex X X X  X 
BMI X X X X X 
Previous leg 
injury 
X X   X 
Osteoporosis X     
KL grade  X X X  
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Risk factor CPCSSN TOARP Rotterdam 
Study-1 
MOST Nottingham 
Joint damage   X    
T2 cartilage 
relaxation time 
 X    
Genetic risk   X   
Knee pain   X X  
Education level   X   
Smoking   X   
Contralateral/m
ultiple joint 
osteoarthritis  
   X  
Average 
WOMAC score 
   X  
Depression    X  
Knee 
misalignment 
   X  
Occupation     X 
Family history     X 
WOMAC: Western Ontario and McMaster Universities arthritis index 
KL: Kellgren and Lawrence 
 
5.3 Comparison of Dependence Analysis with Existing 
Dependence Analyses 
While no studies have examined the dependence between diabetes, hypertension, and 
osteoarthritis together, several studies have looked at each pair of diseases. The findings of this 
thesis will be compared to the finding of other studies below.  
5.3.1 Diabetes and Hypertension 
Epidemiological and pathophysiological evidence supports an association between diabetes and 
hypertension beyond what would be expected due to shared risk factors (234). Evidence from 
epidemiologic studies found an association between blood pressure and blood glucose; this has 
been observed in both children (235) (where the effect of risk factors such as drugs and alcohol 
are minimal) and adults (236). Higher blood glucose levels have been associated with an 
increased risk of developing hypertension in the future. After an 18-year follow-up, a long-term 
Finnish study of men without hypertension found higher rates of hypertension development 
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among those who had higher blood glucose concentrations at the outset of the study, even after 
adjusting for age, adiposity, alcohol consumption, and baseline blood pressure (237). Similarly, 
increased blood pressure is associated with an increased risk of diabetes. A study of 10000 men 
in Israel found systolic blood pressure to be significantly associated with the development of 
type 2 diabetes after five years (238). Several pathophysiological mechanisms have been 
proposed to explain the association between these two diseases; however, none of these 
definitively explain the relationship (234). 
These findings align with those of the current analysis, which found an association between 
diabetes and hypertension that persisted after adjusting for relevant risk factors. Higher 
probabilities of diabetes and hypertension co-occurrence were estimated using the copula model 
compared to those estimated by assuming independence. 
5.3.2 Diabetes and Osteoarthritis 
A recent systematic review and meta-analysis found diabetes and osteoarthritis to be associated 
(239). Examination of osteoarthritis risk among 32,137 people revealed an odds ratio of 1.46 
(95% confidence interval: 1.08 to 1.96) comparing people with diabetes to those without. Several 
studies retained a significant association after adjusting for obesity (240–242), a considerable 
risk factor for both diseases. A similar association was found for the risk of diabetes among 
people with hypertension. An odds ratio of 1.41 (95% confidence interval:1.21 to 1.65) was 
observed for diabetes development, comparing those with osteoarthritis to those without across a 
group of 1,040,175 people. Interestingly, the association between diabetes and osteoarthritis was 
significant in studies including hand osteoarthritis only (243,244), which highlights the 
metabolic and systemic nature of hand osteoarthritis. Similarly, several studies have observed the 
impact of metabolic syndrome (which includes diabetes) on the risk of osteoarthritis. The 
Japanese Research on Osteoarthritis/Osteoporosis Against Disability (ROAD) study found that 
the development of diseases considered components of metabolic syndrome was associated with 
an increased risk of knee osteoarthritis development and progression (245). In fact, the co-
occurrence of obesity, diabetes, and hypertension (all of which are components of metabolic 
disorder) was found to increase the odds of experiencing hand osteoarthritis by a factor of 2.3 
(95% confidence interval 1.3 to 3.9) (246). 
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In the current analysis, some dependence was observed between diabetes and osteoarthritis (ϕ = 
0.10). However, much of this was likely due to the effect of risk factors, as the observed 
dependence decreased after adjusting for relevant factors (ϕ = 0.04). Accordingly, diabetes and 
osteoarthritis had the lowest θ estimate of the disease pairs that were examined, corresponding to 
the least dependence. As suggested by the literature, an association may exist between diabetes 
and hand osteoarthritis, specifically; however, diagnoses of osteoarthritis within CPCSSN were 
not specific to the joint(s) affected, thus sub-analyses could not be performed. 
5.3.3 Hypertension and Osteoarthritis 
Research investigating the relationship between hypertension and osteoarthritis found an 
association between the two diseases (247–250). A research group in Korea studied hypertension 
and its impact on osteoarthritis and found that while hypertension was not significantly 
associated with osteoarthritis generally (251), it was significantly associated with an increased 
risk of knee osteoarthritis (OR: 1.26, 95% confidence interval: 1.08 to 1.48) (252). Hypertension 
is a component of metabolic disease, which has been linked to the development of osteoarthritis 
(245,246), similar to diabetes. One theory hypothesizes that subchondral ischemia (inadequate 
blood flow to bone tissues) due to the vessel-narrowing effects of hypertension results in 
degradation of the joint cartilage, resulting in osteoarthritis (253–255). 
Results of this thesis revealed an association between hypertension and osteoarthritis as well. 
Correlation assessed via the ϕ coefficient revealed a relationship that persisted after adjustment 
for relevant factors. When using the copula to estimate the trivariate probabilities, the estimated 
probability of the co-occurrence of hypertension and osteoarthritis was greater than the estimated 
probability assuming independence. 
This thesis clearly demonstrated that when making estimations about the risk of multiple 
diseases, it is inappropriate to assume that each disease is independence of the other. Instead, 
models must be used that are able to capture the dependence that exists between diseases and 
express this when estimating risk. 
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5.3.4 Multiple Disease Risk Estimation 
There has been one PPM developed for multiple diseases. Wang et al. (256) developed a model 
for both COPD and congestive heart failure (CHF) using the EMR data of roughly 8000 patients. 
Risk factors used as predictors included musculoskeletal disorders, heart arrhythmias, diabetes, 
tobacco use, and asthma. Rather than considering predictors individually, predictors were 
grouped by selecting those that best predicted the outcome, resulting in three groups: predictors 
for COPD and CHF, predictors of only COPD, and predictors of only CHF. The main objective 
of this study was to identify a set of shared predictors in addition to the development of a model 
that accurately predicts the development of each disease. Predictors such as osteoarthritis, back 
disorders, and cardiac dysrhythmias were shared by CHF and COPD; predictors such as diabetes 
mellitus, chronic ischemic heart disease, and acute ischemic heart disease were mainly associated 
with CHF; and predictors such as asthma, kidney stones, and tobacco use disorder were mainly 
associated with COPD. The resulting predictive model performed well, with an AUC of 0.72. 
Similar to the model developed for this thesis, Wang et al. used EMR data to derive their 
prognostic predictive model. 
5.4 Limitations 
This research has several limitations that should be considered. 
The current analysis was limited by the availability of information within the EMR. Information 
describing key risk factors was unavailable, such as behavioural or environmental factors, as this 
information is not typically collected during a clinical encounter. For the univariate models, this 
likely resulted in an underestimation in the risk of patients who possess the uncollected risk 
factor. For the dependence analysis, this potentially resulted in some of the observed dependence 
being due to a risk factor that was not collected in the EMR. As the risk factor was not collected, 
it could not be adjusted for. Such a factor could act in either direction; a risk factor could 
increase or decrease the dependence between the diseases, thus the true dependence could be less 
than or greater than what was observed. However, the use of information available within the 
EMR has several advantages. The primary care setting is considered an ideal site to deploy 
models to estimate patients’ risk of chronic disease as patients are commonly seen by a PCP 
prior to disease development. EMR data are readily available to base predictions on in primary 
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care; that is, no additional information needs to be collected in order to support the use of a 
predictive model in clinical practice. The model would operate in the background of an EMR, 
assessing the risk of disease among patients and flagging those at increased risk. Additionally, 
analyses based on EMR data are not limited by poor statistical power due to small sample sizes. 
EMR databases often collect the records of thousands of patients, providing sufficient power to 
make strong conclusions. 
Caution must be taken when applying the results to other settings, as the data used are likely not 
representative of the general population. However, as previously mentioned, primary care is an 
excellent setting where predictive models can be used to identify high-risk patients by estimating 
risk of chronic disease. Thus, deriving predictive models in the same setting that they will be 
used is ideal. 
There are several errors that may occur that would result in a diagnosis not being recorded by the 
PCP, resulting in missing data. First, the PCP must correctly identify and diagnose the disease. It 
is possible that a disease may go undetected or undiagnosed and would not be recorded in the 
EMR. Second, the PCP must record the diagnosis in the EMR; diagnoses of certain diseases may 
carry stigma, limiting the PCP's willingness to record the diagnosis in the EMR. For example, a 
diagnosis of schizophrenia sometimes carries stigma; a PCP may want to be completely certain 
of their diagnosis before recording it in the EMR and may not record the diagnosis otherwise. 
Third, in CPCSSN, the diagnosis found in the Billing table corresponds to the diagnosis that is 
most responsible for the visit, or the most responsible diagnosis. The PCP must be sufficiently 
motivated to record any additional diagnoses in the Health Condition table. However, a thorough 
chart review was used to validate the CPCSSN disease-case algorithms that resulted in high 
sensitivity and specificity for these algorithms. Other conditions relied upon case definitions 
created for the purpose of this thesis; these case definitions have not been validated. However, all 
efforts to make these definitions as accurate as possible have been performed, including a review 
of relevant literature; a comprehensive examination of the database; and review by an expert 
EMR user who was a member of the research team (PCP). 
There may have been some bias introduced through patterns in physician diagnosis of diabetes, 
hypertension, and osteoarthritis. For example, should a physician diagnose a patient with 
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diabetes, it is likely that they will assess for related conditions, such as hypertension. In some 
cases, a diagnosis of hypertension would have gone undetected had the physician not diagnosed 
the patient with diabetes. This may have led to some dependence between these diseases being 
due to patterns in diagnosis. 
No external validation was performed for the univariate multivariable models. This would have 
required access to an external data source from a similar yet distinct population. Access to such a 
database was unavailable. Accordingly, the univariate models can only be confidently applied to 
the data from which they were derived. However, the univariate models were intended to be 
specific to the Canadian primary care population and can be confidently applied to this setting. 
The nested nature of the CPCSSN database results in clustered data, in which patients within the 
same group are likely more similar than those in different groups; for example, patients who 
receive care from the same PCP are more likely to be similar than those who receive care from a 
different PCP. This typically requires a methodology capable of accounting for the clustered 
nature of the data; however, linkages between patients and PCPs were unavailable, thus clustered 
analyses were not performed. 
The CPCSSN case definition used to identify patients with diabetes does not separate patients by 
type of diabetes. As such, all diagnoses of diabetes were treated as type 2 diabetes. However, 
these are different diseases with distinct etiologies, each with unique risk factors. Many external 
factors contribute to risk of type 2 diabetes, such as obesity, diet, and smoking (257), whereas 
type 1 diabetes has been linked to more genetic factors (258). This likely resulted in 
misclassification bias. However, the amount of bias introduced was likely minimal, as type 1 
diabetes makes up only 10% of all cases of diabetes, based on national statistics (259). 
Additionally, type 1 diabetes is usually diagnosed in childhood. Given that only incident cases of 
diabetes in adults (18 or above) are being considered, these cases are more likely to be type 2 
where adult onset is more common. Similarly, diagnoses of osteoarthritis did not specify which 
joint was affected. Thus, osteoarthritis included any diagnosis of osteoarthritis, irrespective of 
location. 
  
74 
5.5 Implications 
Although constructed for the purpose of developing a combined prognostic predictive model for 
diabetes, hypertension, and osteoarthritis, the univariate models developed for this thesis could 
be used to independently estimate a patient's risk of each disease. External validation should be 
performed prior to deployment; however, each model's strong internal validation in a Canadian 
primary care population indicates that these models would perform well in a primary care setting 
in Canada. For example, the univariate model for diabetes development could be used by PCPs 
to estimate a patient’s risk of developing diabetes in the next 5 years. This model could either 
operate in the background, flagging high-risk patients, or as requested by the PCP where they 
desire a risk estimate. The PCP can then suggest interventions aimed at reducing the patient’s 
risk of developing diabetes. 
It is widely known that chronic diseases tend to co-occur or cluster within individuals. As 
chronic diseases often have similar risk factors, it is sometimes assumed that this clustering is 
due to their shared risk factors. However, this thesis found that chronic diseases tended to co-
occur more frequently than can be explained by their risk factors. This could be a result of many 
factors such as patient susceptibility or shared disease processes. Irrespective of the mechanism 
resulting in this dependence, a thorough understanding of the dependence between diseases is 
necessary to enable the construction of a prognostic predictive model for the development of 
multiple chronic diseases. This work examined the dependence between diseases using a variety 
of techniques including correlation, partial correlation, and copula modelling. Based on these 
methods, this thesis confirms the findings of previous works that have also demonstrated 
dependence between diabetes, hypertension, and osteoarthritis (234,239,247–250). However, this 
thesis is the first to do so using a method that accounts for the non-Gaussian distribution of 
diseases while simultaneously adjusting for relevant risk factors. Based on this dependence 
analysis, trivariate probabilities can be estimated to inform patients and their PCPs about their 
risk of diabetes, hypertension, and osteoarthritis, including the co-occurrence of these diseases. 
The availability of a prognostic predictive model capable of estimating a patient's risk of 
multiple diseases could impact a physician's clinical care in many ways. First, this tool may 
reveal a risk of the development of multiple diseases that is greater than what would be expected 
when estimating disease risk independently; this elevated risk due to the dependence between 
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diseases would likely have gone undetected otherwise. Informed of this risk, physicians can 
suggest preventative interventions accordingly. For example, a patient’s risk of developing 
diabetes and hypertension within the same 5-year window could be estimated by multiplying 
their risk of diabetes by their risk of hypertension. This method assumes that these outcomes are 
independent; however, this assumption is invalid for diabetes and hypertension. Instead, the 
copula model would produce a greater risk of developing these two diseases. The difference 
between these risks could be the difference between the PCP making a recommendation for 
preventative action or not. The most useful and effective way to convey this information must be 
the subject of future work. 
5.6 Future Directions 
The completion of this work enables the construction of a prognostic predictive model for 
diabetes, hypertension, and osteoarthritis. The current model assumes dependence between 
diseases does not vary between individuals, as θ is fixed for all patients after adjusting for risk 
factors. Further research is needed to allow θ to vary depending on the values of a patient’s risk 
factors. 
The model developed in this thesis would present risks that are adjusted for the dependence 
between diseases. Future work must investigate how best to present these risks in a way that is 
meaningful to both patients’ and their PCPs. This will require specific research into how people 
interpret information about joint risk, as this is harder to interpret than a single disease risk. For 
example, does knowledge of increased risk of both diabetes development and hypertension 
development have a different effect compared to knowledge of increased risk of diabetes on its 
own.  
The model can be operationalized into a tool capable of running in the background of an EMR to 
flag high-risk patients and/or deliver risk estimates for patients when called upon by the PCP. 
Future research should assess the effectiveness of this tool, ideally through a randomized 
controlled trial in which PCPs are randomly assigned to receive the tool for use in their clinical 
practice. This trial would assess outcomes such as whether PCPs make different decisions when 
given information about a patient’s risk; whether patients are more likely to adopt a preventative 
change when this recommendation is supported by a risk estimate; whether patient risk is 
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reduced after receiving a risk estimate; and whether patient outcomes are ultimately changed by 
receiving risk estimates. In the primary prevention of multimorbidity, this thesis takes a first step 
in developing a tool capable of delivering risk estimates to inform PCP decision-making. 
5.7 Conclusion 
Through the construction of univariate models for diabetes, hypertension, and osteoarthritis, and 
an examination of the dependence between each of these diseases, this thesis developed a 
prognostic predictive model for the occurrence, including the co-occurrence, of these diseases. 
Univariate models were able to accurately estimate patient risk, as demonstrated by their 
discrimination and calibration. A dependence analysis using copulas to capture the non-Gaussian 
distribution of each disease revealed the correlations between each disease pair. This dependence 
analysis enabled the estimation of the risk of developing any combination of the diseases 
considered. The development and implementation of this model in clinical practice will enable 
accurate risk estimation to inform interventions aimed at risk reduction. 
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Appendices 
Appendix A: Summary of Validation Results for CPCSSN Diseases (193) 
Condition Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
PPV %  
(95% CI) 
NPV %  
(95% CI) 
Hypertension 84.9 
(82.6 to 87.1) 
93.5 
(92.0 to 95.1) 
92.9  
(91.2 to 94.6) 
86.0  
(83.9 to 88.2) 
Diabetes 95.6  97.1  87.0  99.1  
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(93.4 to 97.9) (96.3 to 97.9) (83.5 to 90.5) (98.6 to 99.6) 
Depression 81.1  
(77.2 to 85.0) 
94.8  
(93.7 to 95.9) 
79.6  
(75.7 to 83.6) 
95.2  
(94.1 to 96.3) 
COPD 82.1  
(76.0 to 88.2) 
97.3  
(96.5 to 98.0) 
72.1  
(65.4 to 78.8) 
98.4  
(97.9 to 99.0) 
Osteoarthritis 77.8  
(74.5 to 81.1) 
94.9  
(93.8 to 96.1) 
87.7  
(84.9 to 90.5) 
90.2  
(88.7 to 91.8) 
Dementia 96.8  
(93.3 to 100.0) 
98.1  
(97.5 to 98.7) 
72.8  
(65.0 to 80.6) 
99.8  
(99.6 to 100.0) 
Epilepsy 98.6  
(96.6 to 100.0) 
98.7  
(98.2 to 99.2) 
85.6  
(80.2 to 91.1) 
99.9  
(99.7 to 100.0) 
Parkinsonism 98.8  
(96.4 to 100.0) 
99.0  
(98.6 to 99.5) 
82.0  
(74.5 to 89.5) 
99.9  
(99.8 to 100.0) 
COPD: chronic obstructive pulmonary disease; NPV: negative predictive value; PPV: positive 
predictive value 
Appendix B: Risk Factor Case Definitions 
Risk Factor Table Name Value 
Alcohol Billing 
Health Condition 
Encounter Diagnosis 
ICD-9 Codes: 
• 303: Alcohol dependence syndrome 
• 305.0: Non-dependent alcohol abuse 
Health Condition Inclusion: 
• “alcohol” 
Exclusion: 
• “fam” 
• “no” 
• “FAS” 
Encounter Diagnosis Inclusion: 
• “alcohol dependence” 
• “alcohol abuse” 
• “alcoholism” 
Risk Factor Inclusion: 
• “alcohol” 
Exclusion: 
• “no” 
• “alcohol n” 
• “alcohol -” 
Epilepsy Disease Case* Epilepsy 
Stress Billing 
Health Condition 
Encounter Diagnosis 
ICD-9 Codes: 
• 308: Acute reaction to stress 
• 309: Adjustment reaction 
Risk Factor Inclusion: 
• “stress” 
Exclusion: 
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• “no” 
Schizophrenia Billing 
Health Condition 
Encounter Diagnosis 
ICD-9 Code: 
• 295: Schizophrenic disorders 
Health Condition 
Encounter Diagnosis 
Inclusion: 
• “schizo” 
Exclusion: 
• “fam” 
Medication Prescription of second-generation anti-
psychotics: 
• Aripiprazole (Abilify) 
• Asenapine (Saphris) 
• Brexpiprazole (Rexulti) 
• Cariprazine (Vraylar) 
• Clozapine (Clozaril) 
• Iloperidone (Fanapt) 
• Lurasidone (Latuda) 
• Olanzapine (Zyprexa) 
• Paliperidone (Invega) 
• Quetiapine (Seroquel) 
• Risperidone (Risperdal) 
• Ziprasidone (Geodon) 
Prescription of first-generation anti-psychotics: 
• Chlorpromazine 
• Fluphenazine 
• Haloperidol 
• Perphenazine 
Anxiety Billing 
Health Condition 
Encounter Diagnosis 
ICD-9 Code: 
• 300.0: anxiety related neurotic 
disorders 
Health Condition Inclusion: 
• “anxiety” 
Exclusion: 
• “fam” 
Encounter Diagnosis Inclusion: 
• “anxiety” 
Cancer Billing 
Health Condition 
Encounter Diagnosis 
ICD-9 Codes: 
• 140-149: malignant neoplasm of lip, 
oral cavity, and pharynx 
• 150-159: malignant neoplasm of 
digestive organs and peritoneum 
• 160-169: malignant neoplasm of 
respiratory and intrathoracic organs 
• 170-175: malignant neoplasm of bone, 
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connective tissue, skin, and breast 
• 176: Kaposi’s sarcoma 
• 179-189: malignant neoplasm of 
genitourinary organs 
• 190-199: malignant neoplasm of other 
and unspecified sites 
• 200-208: malignant neoplasm of 
lymphatic and hematopoietic tissue 
• 209: neuroendocrine tumours 
• 239: neoplasms of unspecified nature 
Health Condition Inclusion: 
• “cancer” 
• “neoplasm” 
Exclusion: 
• “fam” 
Medication Prescription of chemotherapy drugs: 
• Mechlorethamine (nitrogen mustard, 
Mustargen) 
• Melphalan (Alkeran, L-PAM) 
• Chlorambucil (Leukeran) 
• Cyclophosphamide (Cytoxan, 
Procytox) 
• Ifosfamide (Ifex) 
• Estramustine (Emcyt) 
busulfan (Myleran, Busulfex) 
• Dacarbazine (DTIC) 
• Temozolomide (Temodal) 
• Carmustine (BiCNU, BCNU) 
• Lomustine (CeeNU, CCNU) 
• Streptozocin (Zanosar) 
• Cisplatin (Platinol AQ, Platinol) 
• Carboplatin (Paraplatin, Paraplatin AQ) 
• Oxaliplatin (Eloxatin) 
• Thiotepa (ThioTEPA) 
• Methotrexate 
• Raltitrexed (Tomudex) 
• Pemetrexed (Alimta) 
• Cladribine (Leustatin) 
• Fludarabine (Fludara) 
• Mercaptopurine (Purinethol, 6-MP) 
• Thioguanine (Lanvis, 6-TG) 
• Azactidine (Vidaza) 
• Capecitabine (Xeloda) 
• Cytarabine (Cytosar, Ara-C) 
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• 5-fluorouracil (Adrucil, 5-FU, Efudex 
[topical]) 
• Gemcitabine (Gemzar) 
• Bleomycin (Blenoxane) 
• Dactinomycin (Cosmegen, 
actinomycin-D) 
• Daunorubicin (Cerubidine, 
daunomycin) 
• Doxorubicin (Adriamycin) 
• Epirubicin (Pharmorubicin) 
• Idarubicin (Idamycin) 
• Mitomycin (Mutamycin) 
• Mitoxantrone (Novantrone) 
• Liposomal daunorubicin (DaunoXome) 
• Liposomal doxorubicin (Myocet) 
• Pegylated liposomal doxorubicin 
(Caelyx) 
• Asparaginase (Kidrolase) 
• Docetaxel (Taxotere) 
• Paclitaxel (Taxol) 
• Vinblastine (Velbe) 
• Vincristine (Oncovin) 
• Vinorelbine (Navelbine) 
• Vindesine (Eldesine) 
• Irinotecan (Camptosar) 
• Topotecan (Hycamtin) 
• Etoposide (Vepesid, VP-16) 
• Teniposide (Vumon, VM-26) 
• Hydroxyurea (Hydrea) 
• Octreotide (Sandostatin, Sandostatin 
LAR) 
• Mitotane (Lysodren) 
• Procarbazine hydrochloride (Matulane) 
• Arsenic trioxide 
• Pofimer sodium (Photofrin) 
• Altretamine (Hexalen, Hexastat) 
Cardiovascular 
Disease 
Billing 
Health Condition 
Encounter Diagnosis 
ICD-9 Codes: 
• 410-414: ischemic heart disease 
• 415-417: diseases of pulmonary 
circulation 
• 420-429: other forms of heart disease 
Health Condition 
Encounter Diagnosis 
Inclusion: 
• “cardiovascular disease” 
• “CVD” 
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• “coronary artery disease” 
• “CAD” 
• “heart attack” 
• “myocardial infarction” 
• “heart disease” 
Exclusion: 
• “fam” 
 Medication Prescription of anticoagulant medications: 
• Rivaroxaban (Xarelto) 
• Dabigatran (Pradaxa) 
• Apixaban (Eliquis)  
• Heparin (various) 
• Warfarin (Coumadin) 
Prescription of antiplatelet agents: 
• Clopidogrel (Plavix) 
• Dipyridamole 
• Prasugrel (Effient) 
• Ticagrelor (Brilinta) 
Diabetes Disease Case* Diabetes 
COPD Disease Case* COPD 
Rheumatoid 
Arthritis 
Billing 
Health Condition 
Encounter Diagnosis 
ICD-9 Code: 
• 714: rheumatoid arthritis and other 
inflammatory polyarthropathies 
Health Condition 
Encounter Diagnosis 
Inclusion: 
• “rheumatoid arthritis” 
Exclusion: 
• “fam” 
Hypertension Disease Case* Hypertension 
Lipid Disorder Billing 
Health Condition 
Encounter Diagnosis 
ICD-9 Code: 
• 272: disorders of lipid metabolism 
Health Condition Inclusion: 
• “lipid” 
• “cholesterol” 
Exclusion: 
• “fam” 
Lab LDL measurement: 3.37-9 mmol/L 
Medications Inclusion: 
• “statin” 
Exclusion: 
• “nystatin” 
Bipolar Affective 
Disorder 
Billing 
Health Condition 
Encounter Diagnosis 
ICD-9: 
• 296.4: bipolar affective disorder, manic 
• 296.5: bipolar affective disorder, 
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depressed 
• 296.6: bipolar affective disorder, mixed 
• 296.7: bipolar affective disorder, 
unspecified 
Health Condition 
Encounter Diagnosis 
Inclusion: 
• “bipolar” 
Exclusion: 
• “fam” 
Chronic Kidney 
Disease 
Billing 
Health Condition 
Encounter Diagnosis 
ICD-9: 
• 585: chronic renal failure 
Health Condition 
Encounter Diagnosis 
Inclusion: 
• “chronic kidney disease” 
• “CKD” 
• “chronic renal failure” 
Exclusion: 
• “fam” 
Lab Occurrence of the following laboratory results: 
• Estimated glomerular filtration rate 
(eGFR) less than 60 mL/min/1.73 m2 
(260) 
• Serum creatinine greater than 120 
mol/L for men or 90 mol/L for 
women (261) 
• Urine albumin/creatinine ratio greater 
than 20 mg/mmol for men or 28 
mg/mmol for women (84) 
• Serum albumin greater than 300 mg/L 
(260) 
Tricyclic 
Antidepressant 
(TCA) use 
Medication Prescription of: 
• Amitriptyline 
• Amoxapine 
• Desipramine (Norpramin) 
• Doxepin 
• Imipramine (Tofranil) 
• Nortriptyline (Pamelor) 
• Protriptyline (Vivactil) 
• Trimipramine (Surmontil) 
Osteoporosis Billing 
Health Condition 
Encounter Diagnosis 
ICD-9 Code: 
• 733: Osteoporosis and other bone 
disorders 
Health Condition 
Encounter Diagnosis 
Inclusion: 
• “osteoporosis” 
Exclusion: 
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• “fam” 
Medications Prescription of: 
• Alendronic acid 
• Risedronic acid 
• Ibandronic acid 
Leg Injury Billing 
Health Condition 
Encounter Diagnosis 
 
ICD-9 Codes: 
• 820-29: fracture of lower limb 
• 843: sprain or strain of hip and thigh 
• 844: sprain or strain of knee and leg 
• 928: crushing injury to lower limb 
BMI Exam Based on: 
• BMI (kg/m2) as recorded in EMR 
• Height (m) and weight (kg) as recorded 
in the EMR on the same date 
Family History of 
Osteoarthritis 
Family History Inclusion: 
• “osteoarthritis” 
Exclusion: 
• “no” 
Family History of 
Diabetes 
Family History Inclusion: 
• “diabet” 
Exclusion: 
• “no” 
Family History of 
Hypertension 
Family History Inclusion: 
• “hypertens” 
Exclusion: 
“no” 
Family History of 
Depression 
Family History Inclusion: 
• “depress” 
Exclusion: 
“no” 
Stroke Billing 
Health Condition 
Encounter Diagnosis 
ICD-9 Codes: 
• 430: Subarachnoid hemorrhage 
• 431: Intracerebral hemorrhage 
• 432: Other and unspecified intracranial 
hemorrhage 
• 434: Occlusion of cerebral arteries 
Health Condition 
Encounter Diagnosis 
Inclusion: 
• “stroke” 
Exclusion: 
• “fam” 
Asthma Billing 
Health Condition 
Encounter Diagnosis 
ICD-9 Code: 
• 493: Asthma 
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 Health Condition 
Encounter Diagnosis 
Inclusion: 
• “asthma” 
Exclusion: 
• “fam” 
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